Patent Application
20120035320
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 29, 2011, is named 17023104.txt and is 73,787 bytes in size.
Researchers have investigated various gene therapy methods in order to develop techniques that could deliver a therapeutic gene (transgene) to selected cells in which proper gene expression is desired. Such methods need to protect the transgene against degradation by nucleases in extracellular matrices, bring the transgene across the plasma membrane and into the nucleus of target cells, and have no detrimental effects.
Scientists have successfully used viral vectors to mediate gene transfer with high efficiency and the possibility of long-term gene expression, but safety concerns have not yet been adequately overcome. Other practical issues with respect to viral vector gene transfer relate to size limitations (i.e., the size of the transgene that recombinant viruses can carry) and difficulties in the production of viral vectors. Many studies have investigated methods of non-viral gene delivery using physical (carrier-free gene delivery) and chemical approaches (synthetic vector-based gene delivery). Chemical approaches use synthetic or naturally occurring compounds as carriers to deliver the transgene into cells. Although significant progress has been made in the basic science and applications of various non-viral gene delivery systems, the majority of nonviral approaches are still much less efficient than viral vectors, especially for in vivo gene delivery.
The present invention provides a nucleic acid delivery peptide complex, comprising
operably linked to
Cys-L1-R1
wherein Acr is an acridine; A1 is Lysine, Arginine, Leucine or Glutamic acid; A2 is 1 to 6 amino acids; Cys is cysteine, wherein the Cys is bound to L1 at the amino-terminus, the carboxy-terminus or an amino acid side-chain; and n is 1 to 10; wherein L1 is a linker; wherein R1 is one or more of a peptide, polyethylene glycol (PEG), a carbohydrate, biotin or avidin, and/or is a hydrogen; and wherein the nucleic acid delivery peptide reversibly binds to nucleic acid.
As used herein, the Cys-L1-R1 moiety may be linked to the acridine-peptide moiety at the amino-terminus of the acridine-peptide moiety, at the carboxy-terminus of the acridine-peptide moiety, or at one of the side chains of the amino acids that make up the of the acridine-peptide moiety. For example the structure of the peptide may be as follows in Formula Ia, I b, Ic or Id:
In certain embodiments, L1 is —S—; a disulfide linkage; a maleimide linkage; an amide linkage, ester linkage, ether linkage, or a thiol ether linkage, hydrazone linkage.
In certain embodiments, R1 is a carbohydrate, such as a targeting ligand. In certain embodiments, the carbohydrate is a triantennary N-glycan, such as a high-mannose N-glycan. In certain embodiments, the carbohydrate is Man9GlcNAc2.
In certain embodiments, R1 is a peptide, such as a nuclear localization signal (NLS) peptide, a fusogenic peptide, a targeting peptide, an NLS-fusogenic peptide, or an enzyme. In certain embodiments, the R1 peptide is NLS (SEQ ID NO: 45); Cys NLS (SEQ ID NO: 46); Control NLS (SEQ ID NO: 47); Cys-Control NLS (SEQ ID NO: 48); Mal-Gly-Control-NLS (SEQ ID NO: 49); Melittin (natural melittin) (SEQ ID NO: 50); Cys-melittin (SEQ ID NO: 51); K-Melittin (SEQ ID NO: 52); Cys-K-Melittin (SEQ ID NO: 53); Mal-Gly-K-Melittin (maleimide) (SEQ ID NO: 54); Cys-K-Melittin-NLS (SEQ ID NO: 55); Cys-NLS-K-Melittin (SEQ ID NO: 56); Modified Cys-NLS-Melittin (SEQ ID NO: 57); PC4—NLS Analogue Cys-PC4 (SEQ ID NO: 58); PC4—NLS Analogue Maleimide-PC4 (SEQ ID NO: 59); PC4—NLS Analogue Cys-PC4—NLS (SEQ ID NO: 60); PC4—NLS Analogue Cys-NLS-PC4 (SEQ ID NO: 61); Cys-JTS (SEQ ID NO: 62) or Octreotide.
In certain embodiments, R1 is polyethylene glycol (PEG). In certain embodiments, the PEG is between 500 g/mol and 20,000 g/mol, such as 10,000 g/mol, 5,000 g/mol, 2,000 g/mol or 500 g/mol.
In certain embodiments, L1 is a maleimide linkage. In certain embodiments, L1 is a disulfide linkage.
In certain embodiments, A1 is Lys having an c-amine, and Acr is linked to the ε-amine of Lys.
In certain embodiments, A2 is one or more of any of the natural 20 amino acids or any other unnatural amino acids. In certain embodiments, A2 is one or more of Arg, Lys, Glu or Leu. In certain embodiments, A2 is 1 to 6 Lys residues. In certain embodiments, A2 is 1 to 6 Arg residues. In certain embodiments, A2 is 1 to 6 Glu residues. In certain embodiments, A2 is 1 to 6 Leu residues. In certain embodiments, A2 is 1 to 4 amino acids. In certain embodiments, A2 is 1 or 2 amino acids.
In certain embodiments, n is 1 to 8. In certain embodiments, n is 3 to 6.
In certain embodiments, Acr is a substituted acridine. In certain embodiments, Acr is a 9-aminoacridine, such as 9-aminoacridine is 9-alkylaminoacridine, 9-arylaminoacridine, 9-(N-carboxamido) acridine or 9-ureidoacridine.
The present invention provides a nucleic acid delivery peptide complex, comprising Formula II:
In certain embodiments, the melittin is Melittin (natural melittin); Cys-melittin (SEQ ID NO: 52); K-Melittin (SEQ ID NO: 53); Cys-K-Melittin (SEQ ID NO: 54); Mal-Gly-K-Melittin (maleimide) (SEQ ID NO: 55); Cys-K-Melittin-NLS (SEQ ID NO: 56); Cys-NLS-K-Melittin (SEQ ID NO: 57); or Modified Cys-NLS-Melittin (SEQ ID NO: 58). In certain embodiments, A1 is Arginine and A2 is Arginine.
The present invention provides a nucleic acid delivery peptide complex, comprising Formula III:
wherein Acr is acridine; A3 is Cys or Cys-Trp; and n is 1 to 6; wherein the nucleic acid delivery peptide complex binds to nucleic acid.
In certain embodiments, n is 5. In certain embodiments, PEG is between 500 g/mol and 20,000 g/mol.
The present invention provides a nucleic acid delivery peptide complex, comprising Formula IV:
wherein L3 is a linker, and n is 4-6. In certain embodiments, the linker is an acetamide linkage or a maleimide linkage. In certain embodiments, the compound is Formula IVa:
In certain embodiments the compound is Formula IVb:
The present invention provides a peptide complex of poly(Acr-Arg)4-SS-melittin (SEQ ID NO: 78); poly(Acr-Arg)4-Mal-melittin (SEQ ID NOS 11 & 67, respectively); PEG-Cys-Trp-(Lys(Acr))3 (SEQ ID NO: 3); PEG-Cys-Trp-(Lys(Acr))4 (SEQ ID NO: 4); PEG-Cys-Trp-(Lys(Acr))5 (SEQ ID NO: 5); Man9-Mal-Cys-(Lys(Acr))4 (SEQ ID NO: 6); poly(Acr-Arg)4-SS-PEG (SEQ ID NO: 7); poly(Acr-Arg)4-Mal-PEG (SEQ ID NO: 8).
The present invention provides a nucleic acid delivery complex comprising a nucleic acid molecule reversibly bound to one or more of the peptide complexes described above. In certain embodiments, the nucleic acid is an RNA molecule or a DNA molecule, such as a double-stranded RNA or DNA molecule.
The present invention provides an anionic open polyplex comprising a nucleic acid molecule reversibly bound to a nucleic acid delivery peptide complex comprising
operably linked to
Cys-L1-R1
wherein Acr is an acridine; A1 is Lysine, Arginine, Leucine or Glutamic acid; A2 is 1 to 6 amino acids; Cys is cysteine, wherein the Cys is bound to L1 at the amino-terminus, the carboxy-terminus or an amino acid side-chain; and n is 1 to 10; wherein L1 is a linker; wherein R1 is one or more of a peptide, polyethylene glycol (PEG), a carbohydrate, biotin or avidin and/or is a hydrogen; and wherein the nucleic acid delivery peptide complex reversibly binds to nucleic acid, wherein the anionic open polyplex is stable against DNase or RNase digestions. As used herein, the term “stable against DNase or RNase digestions” means that at least 60% of the original anionic open polyplex remains after incubation at 37° C. for 1 hour. Anionic open polyplex is a DNA or RNA peptide complex in which the DNA or RNA remains stable for 1 hour when reacted with up to 60 milli-units (International Units) of DNase or RNase.
The present invention provides an anionic open polyplex comprising a nucleic acid molecule reversibly bound to a nucleic acid delivery peptide complex comprising Formula Ia, Ib, Ic, Id, II, III, IV, IVa or IVb wherein the nucleic acid delivery peptide complex reversibly binds to nucleic acid, wherein the anionic open polyplex is stable against DNase or RNase digestions.
In certain embodiments, the anionic open polyplex is electronegatively charged. In certain embodiments, the anionic open polyplex has a diameter of 100 nm or greater, where the definition of diameter is the longest end-to-end distance spanning the polyplex as determined by atomic force microscopy. In certain embodiments, the anionic open polyplex possesses a shape that is similar to uncomplexed DNA or RNA, i.e., where the shape is a random coil. In certain embodiments, the anionic open polyplex has a long circulatory half-life, such as, for example, a beta pharmacokinetic half-life of 60 minutes or greater.
The present invention provides a composition including a polyplex of as described above and a physiologically acceptable carrier.
The present invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, by administering to a mammal in need of such therapy, an effective amount of nucleic acid polyplex or nucleic acid delivery complex as described above.
The present invention provides a nucleic acid polyplex or nucleic acid delivery complex for use in medical therapy.
The present invention provides the use of nucleic acid polyplex or nucleic acid delivery complex for the manufacture of a medicament useful for the treatment of a pathological condition or symptom in a mammal.
The present invention provides a nucleic acid delivery peptide complex comprising:
The present invention provides a nucleic acid delivery peptide complex, comprising
operably linked to
-L1-R1
wherein Lysacr is a lysine modified with acridine at the s-amine; Cys is Cysteine; Lys is Lysine; Y is Lys or a covalent bond; Z is Lysine, Arginine, Leucine, Phenylalanine, or Cysteine, wherein Z is optionally conjugated by a maleimide linkage to poly(ethylene glycol); and n is 1 to 30; and wherein L1 is a linker and is bound to Cys at the amino-terminus, the carboxy-terminus or an amino acid side-chain; wherein; wherein R1 is one or more of a peptide, polyethylene glycol (PEG), a carbohydrate, and/or is a hydrogen; and wherein the nucleic acid delivery peptide reversibly binds to nucleic acid.
The nucleic acid delivery peptide complex of the present invention comprising several moieties: a peptide backbone to which acridines can be bonded, possibly one or more functional moieties, and a linker that operably links the peptide backbone to the functional moiety/moieties. In certain embodiments, a nucleic acid molecule is reversibly bound to one or more of the peptide complexes described above. The present invention further provides an anionic open polyplex comprising a nucleic acid molecule reversibly bound to a nucleic acid delivery peptide complex.
Acridines
Acridine, C13H9N, is an organic compound that is a colorless solid that is commonly used for dyes and drugs. Acridine and related derivatives bind to DNA and RNA due to their abilities to intercalate. As used herein the term “acridine” is used to mean substituted or unsubstituted acridine and their related derivatives. Examples of substituted acridines are known in the literature, such as in Table 1 of Teh Kuei Che, Rosario Fico and E. S. Canellakis “Diacridines, Bifunctional Intercalators. Chemistry and Antitumor Activity, J. Medicinal Chemistry, (1978) 21, 868-874 and in Table 2 of Marc O. Anderson, John Sherrill, Peter B. Madrid, Ally P. Liou, Jennifer L. Weisman, Joseph L. DeRisi, and R. Kiplin Guy “Parallel Synthesis of 9-Aminoacridines and their evaluation against Cloroquine-resistant Plasmodium Falciparum” Bioorganic and Medicinal Chemistry, (2006) 14, 334-343.
Peptide Backbones
The nucleic acid delivery peptide complexes of the present invention contain a peptide backbone. In certain embodiments, the backbone is (A1-A2)n, where A1 and A2 are amino acids, and n is 1-10, or the backbone is (Lys)n (SEQ ID NO: 44), where n is 1-6. In certain embodiments, A1 is Lysine, Arginine, Leucine or Glutamic acid and A2 is 1 to 6 amino acids. In certain embodiments, a cysteine residue is bonded to(A1-A2)n at the amino-terminus, the carboxy-terminus or an amino acid side-chain of A2.
The term “amino acid” includes the residues of the natural amino acids (e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, H is, Hyl, Hyp, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in Dextrorotary or Levorotary stereoisomeric forms, as well as unnatural amino acids (e.g., phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, and gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citruline, alpha-methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine). The term also comprises natural and unnatural amino acids (Dextrorotary and Levorotary stereoisomers) bearing a conventional amino protecting group (e.g. acetyl or benzyloxycarbonyl), as well as natural and unnatural amino acids protected at the carboxy terminus (e.g., as a (C1-C6)alkyl, phenyl or benzyl ester or amide; or as an α-methylbenzyl amide). Other suitable amino and carboxy protecting groups are known to those skilled in the art (See for example, Greene, T. W.; Wutz, P. G. M., Protecting Groups In Organic Synthesis; second edition, 1991, New York, John Wiley & sons, Inc, and documents cited therein). An amino acid can be linked to the remainder of a compound of formula (I) through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of cysteine.
The term “peptide” describes a sequence of 2 to 25 amino acids (e.g. as defined hereinabove) or peptidyl residues. The sequence may be linear or cyclic. For example, a cyclic peptide can be prepared or may result from the formation of disulfide bridges between two cysteine residues in a sequence. A peptide can be linked to the remainder of a compound of formula I through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of a cysteine. Peptide derivatives can be prepared as disclosed in U.S. Pat. Nos. 4,612,302; 4,853,371; and 4,684,620, or as described in the Examples hereinbelow. Peptide sequences specifically recited herein are written with the amino terminus on the left and the carboxy terminus on the right.
The terms “protein,” “peptide” and “polypeptide” are used interchangeably herein.
Linking Groups
In the present invention L1 is a linking group that links the peptide backbone to a functional group. In certain embodiments L1 is —S—, a disulfide linkage, a maleimide linkage, an amide linkage, ester linkage, ether linkage, a thiol ether linkage, a hydrazone linkage, or an acetamide linkage.
Functional Moieties
In embodiments of the present invention R1 is linked to the peptide backbone. In certain embodiments, R1 is a peptide different from the peptide backbone, polyethylene glycol (PEG), a carbohydrate, biotin or avidin, and/or is hydrogen.
In certain embodiments, R1 is a carbohydrate, such as a targeting ligand. In certain embodiments, the carbohydrate is a triantennary N-glycan, such as a high-mannose N-glycan. In certain embodiments, the carbohydrate is Man9GlcNAc2.
In certain embodiments, R1 is polyethylene glycol (PEG). In certain embodiments, the PEG is between 500 g/mol and 20,000 g/mol, such as 10,000 g/mol, 5,000 g/mol, 2,000 g/mol or 500 g/mol.
In certain embodiments, R1 is a peptide, such as a nuclear localization signal (NLS) peptide, a fusogenic peptide, a targeting peptide, an NLS-fusogenic peptide. In certain embodiments, the R1 peptide is NLS; Cys NLS; Control NLS; Cys-Control NLS; Mal-Gly-Control-NLS; Melittin (natural melittin); Cys-melittin; K-Melittin; Cys-K-Melittin; Mal-Gly-K-Melittin (maleimide); Cys-K-Melittin-NLS; Cys-NLS-K-Melittin; Modified Cys-NLS-Melittin; PC4—NLS Analogue Cys-PC4; PC4—NLS Analogue Maleimide-PC4; PC4—NLS Analogue Cys-PC4—NLS; PC4—NLS Analogue Cys-NLS-PC4; Cys-JTS or Octreotide (SEQ ID NOS 45-63, respectively).
Examples of R1 peptides that are linked to the peptide-acridine moiety are the following:
GPKK
KRKV
G
In certain embodiments, the functional moiety is a protein, such as an enzyme. Examples of proteins include enzymes, such as phospholipase A2 (PLA2). In certain embodiments of the present invention, more than one functional moiety is linked to the peptide backbone. For example, a NLS and a PEG are linked to the peptide backbone. In another embodiment,
Nucleic Acid Delivery Peptide Complexes
The present invention provides a nucleic acid delivery peptide complex, comprising
operably linked to
Cys-L1-R1
wherein Acr is an acridine; A1 is Lysine, Arginine, Leucine or Glutamic acid; A2 is 1 to 6 amino acids; Cys is cysteine, wherein the Cys is bound to L1 at the amino-terminus, the carboxy-terminus or an amino acid side-chain; and n is 1 to 10; wherein L1 is a linker; wherein R1 is one or more of a peptide, polyethylene glycol (PEG), a carbohydrate, biotin or avidin and/or is a hydrogen; and wherein the nucleic acid delivery peptide complex reversibly binds to nucleic acid.
The present invention provides a nucleic acid delivery peptide complex having the following structure as indicated in Formula Ia, I b, Ic or Id:
The present invention provides a nucleic acid delivery peptide complex, comprising Formula II:
The present invention provides a nucleic acid delivery peptide complex, comprising Formula III:
wherein L1 is a linker, and n is 4-6. In certain embodiments, the linker is an acetamide linkage or a maleimide linkage.
In certain embodiments, the compound is Formula IVa:
In certain embodiments the compound is Formula IVb:
In certain embodiments, the binding of a nucleic acid delivery peptide complex to a nucleic acid molecule forms an anionic open polyplex.
In certain embodiments, the nucleic acid delivery peptide complex comprises:
Nucleic Acids of the Present Invention
In certain embodiments, the nucleic acid delivery peptide complex of the present invention is reversibly bound to a nucleic acid molecule.
The term “nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, composed of monomers (nucleotides) containing a sugar, phosphate and a base which is either a purine or pyrimidine. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues. A “nucleic acid fragment” is a fraction of a given nucleic acid molecule. Deoxyribonucleic acid (DNA) in the majority of organisms is the genetic material while ribonucleic acid (RNA) is involved in the transfer of information contained within DNA into proteins. The term “nucleotide sequence” refers to a polymer of DNA or RNA that can be single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases capable of incorporation into DNA or RNA polymers. The terms “nucleic acid,” “nucleic acid molecule,” “nucleic acid fragment,” “nucleic acid sequence or segment,” or “polynucleotide” may also be used interchangeably with gene, cDNA, DNA and RNA encoded by a gene.
The invention encompasses isolated or substantially purified nucleic acid compositions. In the context of the present invention, an “isolated” or “purified” RNA or DNA molecule is an RNA or DNA molecule that exists apart from its native environment and is therefore not a product of nature. An isolated RNA or DNA molecule may exist in a purified form or may exist in a non-native environment such as, for example, in a transgenic host cell or bacteriophage. For example, an “isolated” or “purified” nucleic acid molecule, or biologically active portion thereof, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In one embodiment, an “isolated” nucleic acid is free of sequences that naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. A protein that is substantially free of cellular material includes preparations of protein or polypeptide having less than about 30%, 20%, 10%, 5%, (by dry weight) of contaminating protein. When the protein of the invention, or biologically active portion thereof, is recombinantly produced, preferably culture medium represents less than about 30%, 20%, 10%, or 5% (by dry weight) of chemical precursors or non-protein-of-interest chemicals. Fragments and variants of the disclosed nucleotide sequences and proteins or partial-length proteins encoded thereby are also encompassed by the present invention. By “fragment” or “portion” is meant a full length or less than full length of the nucleotide sequence encoding, or the amino acid sequence of, a polypeptide or protein.
The term “gene” is used broadly to refer to any segment of nucleic acid associated with a biological function. Thus, genes include coding sequences and/or the regulatory sequences required for their expression. For example, gene refers to a nucleic acid fragment that expresses mRNA, functional RNA, or specific protein, including regulatory sequences. Genes also include nonexpressed DNA segments that, for example, form recognition sequences for other proteins. Genes can be obtained from a variety of sources, including cloning from a source of interest or synthesizing from known or predicted sequence information, and may include sequences designed to have desired parameters.
A “transgene” refers to a gene that has been introduced into the genome by transformation and is stably maintained. Transgenes may include, for example, DNA that is either heterologous or homologous to the DNA of a particular cell to be transformed. Additionally, transgenes may comprise native genes inserted into a non-native organism, or chimeric genes. The term “endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene not normally found in the host organism but that is introduced by gene transfer.
A “variant” of a molecule is a sequence that is substantially similar to the sequence of the native molecule. For nucleotide sequences, variants include those sequences that, because of the degeneracy of the genetic code, encode the identical amino acid sequence of the native protein. Naturally occurring allelic variants such as these can be identified with the use of well-known molecular biology techniques, as, for example, with polymerase chain reaction (PCR) and hybridization techniques. Variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated, for example, by using site-directed mutagenesis that encode the native protein, as well as those that encode a polypeptide having amino acid substitutions. Generally, nucleotide sequence variants of the invention will have at least 40, 50, 60, to 70%, e.g., preferably 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, to 79%, generally at least 80%, e.g., 81%-84%, at least 85%, e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, to 98%, sequence identity to the native (endogenous) nucleotide sequence.
A “functional RNA” refers to an antisense RNA, ribozyme, RNA interference molecule, or other RNA that is not translated.
The term “RNA transcript” refers to the product resulting from RNA polymerase catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. “Messenger RNA” (mRNA) refers to the RNA that is without introns and that can be translated into protein by the cell.
Compositions and Methods of Use
The present invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, by administering to the mammal a nucleic acid delivery peptide complex or an anionic open polyplex
The present invention provides a nucleic acid delivery polyplex or a nucleic acid delivery complex for use in medical therapy.
Further, the compounds of the present invention can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
The compounds of the present invention can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
Thus, the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.
The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
Examples of useful dermatological compositions which can be used to deliver the compounds of formula Ito the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
In general, however, a suitable dose will be in the range of from about 0.4 μg/kg to about 100 mg/kg body weight of the recipient per day, e.g., from about 10 to about 75 μg/kg of body weight per day, such as 3 to about 50 μg/kg, such as in the range of 6 to 90 μg/kg/day, such as in the range of 15 to 60 μg/kg/day. In one embodiment, the dose is 40 μg/kg/day.
The compound is conveniently formulated in unit dosage form; for example, containing 0.1 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form. In one embodiment, the invention provides a composition comprising a compound of the invention formulated in such a unit dosage form. In certain embodiments the formulated dosage form in humans is approximately 0.1-100 mg DNA plus 0.1-100 mg of delivery peptides assuming a 90 kg patient. In certain embodiments the dose is 0.1-4 mg of DNA plus 0.1 to 4 mg of delivery peptide, assuming a 90 kg patient. One of ordinary skill in the art would be able to modify the dosage based on the body weight of the subject.
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
Compounds of the invention can also be administered in combination with other therapeutic agents, for example, other agents that are useful as antibiotics. Examples of such agents include a protein synthesis inhibitor, a cell wall growth inhibitor, a cell membrane synthesis inhibitor, a nucleic acid synthesis inhibitor, or a competitive enzyme inhibitor. In certain embodiments, the additional agent is an antibiotic such as penicillin, ampicillin, amoxicillin, vancomycin, cycloserine, bacitracin, cephalolsporin, imipenem, colistin, methicillin, streptomycin, kanamycin, tobramycin, gentamicin, tetracycline, chlortetracycline, doxycycline, chloramphenicol, lincomycin, clindamycin, erythromycin, oleandomycin, polymyxin nalidixic acid, rifamycin, rifampicin, gantrisin, trimethoprim, isoniazid, paraminosalicylic acid, or ethambutol.
Accordingly, in one embodiment the invention also provides a composition comprising a compound of the present invention, at least one other therapeutic agent, and a pharmaceutically acceptable diluent or carrier. The invention also provides a kit comprising a compound of the present invention, at least one other therapeutic agent, packaging material, and instructions for administering the compound of the present invention or the pharmaceutically acceptable salt thereof and the other therapeutic agent or agents to an animal.
As used herein, the term “therapeutic agent” refers to any agent or material that has a beneficial effect on the mammalian recipient. Thus, “therapeutic agent” embraces both therapeutic and prophylactic molecules having nucleic acid or protein components.
“Treating” as used herein refers to ameliorating at least one symptom of, curing and/or preventing the development of a given disease or condition.
The following definitions are used, unless otherwise described. Alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as propyl embraces only the straight chain radical, a branched chain isomer such as isopropyl being specifically referred to. Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic. Heteroaryl encompasses a radical of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X) wherein X is absent or is H, O, (C1-C4)alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic heterocycle of about eight to ten ring atoms comprising one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X).
The term saccharide includes monosaccharides, disaccharides, trisaccharides and polysaccharides. The term includes glucose, sucrose fructose and ribose, as well as deoxy sugars such as deoxyribose and the like. Saccharide derivatives can conveniently be prepared as described in International Patent Applications Publication Numbers WO 96/34005 and 97/03995. A saccharide can conveniently be linked to the remainder of a compound of formula I through an ether bond.
The invention will now be illustrated by the following non-limiting Examples.
The combination of a polyacridine peptide modified with a melittin fusogenic peptide results in a potent gene transfer agent. (Baumhover, N. Anderson, K, Fernandez C., and Rice, K. G. “Synthesis of In Vitro Testing of a Potent New Polyacridine-melittin Gene Delivery Peptides” Bioconjugate Chemistry, (2010) 21, 74-83.) Polyacridine peptides of the general formula (Acr-X)n-Cys (SEQ ID NO: 65) were prepared by solid phase peptide synthesis, where Acr is Lys modified on its 8-amine with acridine, X is Arg, Leu or Lys and n is 2, 3 or 4 repeats. The Cys residue was modified by either a maleimide-melittin or a thiolpyridine-Cys-melittin fusogenic peptide resulting in reducible or non-reducible polyacridine-melittin peptides. Hemolysis assays established that polyacridine-melittin peptides retained their membrane lytic potency relative to melittin at pH 7.4 and 5. When combined with plasmid DNA, the membrane lytic potency of polyacridine-melittin peptides was neutralized. Gene transfer experiments in multiple cell lines established polyacridine-melittin peptides mediate expression as efficiently as PEI. The expression was very dependent upon a disulfide bond linking polyacridine to melittin. The gene transfer was most efficient when X is Arg and n is 3 or 4 repeats. These studies establish polyacridine peptides as a novel DNA binding anchor peptide.
An important element of many polyplex non-viral gene delivery systems is a releasable fusogenic peptide that can affect endosomal lysis. The endosomal escape of DNA is especially essential for receptor-targeted gene delivery systems to avoid polyplex degradation by the lysosome.
To improve the endosomal escape of DNA, researchers have incorporated fusogenic peptides, including GALA, KALA (SEQ ID NO: 66), HA2, JTS-1 and melittin, into a non-viral gene delivery system. Most applications in gene delivery have utilized melittin because of its relative ease of chemical synthesis and because its mechanism of membrane lysis has been extensively studied. Melittin has been covalently attached to polylysine, PEI, cationic lipids and even self-polymerized by terminal disulfide bonds and demonstrated to increase in vitro gene transfer efficiency.
While DNA anchoring polymers such as PEI, polylysine, dendrimers and chitosan are known to bind ionically to the phosphate backbone of plasmid DNA, this strategy leads to the formation of cationic polyplexes that favor in vitro gene transfer but to a much lesser degree in vivo gene transfer. This is partly because positively charged polyplexes bind non-specifically to proteins and cells. Attempts at masking the charge with PEG still results in a residual positive charge as measured by zeta potential. The non-specific binding of PEGylated cation polyplexes in vivo complicates strategies that attempt to combine a receptor ligand and releasable fusogenic peptide into a non-viral delivery system. Consequently, it would be beneficial to reversibly bind fusogenic peptides, receptor ligand and PEG to DNA while simultaneously controlling the charge of polyplexes. Likewise, it would be advantageous if the DNA binding anchor were sufficiently small in size to allow for its chemical manipulation and specific functionalization with PEG, targeting ligand and fusogenic peptide.
Polyacridine peptides can reversibly bind with high affinity by intercalating into double stranded DNA. It is possible to synthesize a divalent acridine neoglycopeptide for delivery of DNA to the cells expressing the asialoglycoprotein receptor. Further, polyacridine-nuclear localization sequences (NLS) possessing up to three acridines were shown to improve in vitro gene transfer (Shiraishi, T., Hamzavi, R., and Nielsen, P. E. (2005) Targeted Delivery of Plasmid DNA into the Nucleus of Cells via Nuclear Localization Signal Peptide Conjugated to DNA Intercalating Bis- and Trisacridines Bioconjugate Chemistry 16, 1112-1116).
However to date, a polyacridine DNA binding peptide has not been substituted with a fusogenic peptide. The new strategy described herein demonstrates the synthesis of polyacridine-melittin as a DNA binding peptide and establish its efficacy as a potent in vitro gene transfer agent. The results demonstrate that short polyacridine anchor peptides bind to plasmid DNA with sufficient affinity to deliver melittin in vitro and have the potential to control DNA polyplex charge to allow improved in vivo gene delivery.
Materials and Methods
Unsubstituted Wang resin for peptide synthesis, 9-hydroxybenzotriazole, Fmoc-protected amino acids, O-(Benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), 1,3-Diisopropylcarbodiimide (DIC), Fmoc-Lysine-OH, and N-Methyl-2-pyrrolidinone (NMP) were obtained from Advanced ChemTech (Lexington, Ky.). N,N-Dimethylformamide (DMF), trifluoroacetic acid (TFA), and acetonitrile were purchased from Fisher Scientific (Pittsburgh, Pa.). Diisopropylethylamine, piperidine, acetic anhydride, Tris(2-carboxyethyl)-phosphine hydrochloride (TCEP), 9-chloroacridine, maleic anhydride, 2-2′ dithiodipyridine (DTDP), and thiazole orange were obtained from Sigma Chemical Co. (St. Louis, Mo.). Polyethylene amine (PEI 25 KDa) was purchased from Aldrich (Milwaukee, Wis.). D-Luciferin and luciferase from Photinus pyralis were obtained from Roche Applied Science (Indianapolis, Ind.). HepG2, CHO, and 3T3 cells were acquired from the American Type Culture Collection (Manassas, Va.). Inactivated qualified fetal bovine serum (FBS) was from Life Technologies, Inc. (Carlsbad, Calif.). BCA reagent was purchased from Pierce (Rockford, Ill.). pGL3 control vector, a 5.3 kb luciferase plasmid containing a SV40 promoter and enhancer, was obtained from Promega (Madison, Wis.). pGL3 was amplified in a DH5α strain of Escherichia coli and purified according to manufacturer's instructions.
Synthesis of 9-phenoxyacridine and Fmoc Lysine(Acridine)
9-phenoxyacridine was synthesized with modification from the methods of Tung et al. (Boulanger, C., Di Giorgio, C., and Vierling, P. (2005) Synthesis of acridine-nuclear localization signal (NLS) conjugates and evaluation of their impact on lipoplex and polyplex-based transfection. Eur J Med Chem 40, 1295-306.) Briefly, 12 g of phenol (127.5 mmol) and 0.72 g of sodium hydroxide (18 mmol) were heated to 100° C. To the liquified phenol, 2.8 g of 9-chloroacridine (13.105 mmol) was added and stirred vigorously for 1.5 hrs. The reaction was quenched by the addition of 100 ml of 2 M sodium hydroxide then allowed to sit at RT overnight. A yellow precipitate was filtered, washed with water and dried in vacuo (3.4822 g, 12.835 mmoles, 97.9%, M.P. 123-124° C., TLC, 15:5:1:0.5, ethyl acetate/methanol/hexane/acetic acid, Rf=0.18). 1H NMR (DMSO-d6) δ 8.23 (d, 2H), 8.04 (d, 2H), 7.88 (t, 2H), 7.59 (t, 2H), 7.32 (t, 2H), 7.08 (t, 1H), 6.88 (d 2H).
Fmoc-Lysine(Acridine)-OH was prepared by adding 2.18 g of Fmoc-Lys-OH (5.91 mmol) in liquid phenol (6.781 g, 73.01 mmol) to 9-phenoxyacridine (3 g, 11.06 mmol) then heated at 60° C. for 4 hrs under an argon atmosphere. Diethyl ether (80 ml) was then added while stirring vigorously until a yellow precipitate formed that was immediately recovered by filtration and washed repeatedly with diethyl ether. The product was allowed to dry overnight under vacuum (2.90 g, 5.32 mmol, 90%), M.P. 135-140° C., TLC: 1:1, 0.1 v/v % TFA/acetonitrile, Rf=0.75). MS: (M+H+)1+=545.5 m/z. 1H NMR (DMSO-d6) δ 6.7-7.8 (m, 17H), 3.6-3.95 (m, 2H), 3.25-3.53 (br, 3H), 2.06 (m, 1H), 0.8-1.5 (m, 6H).
Synthesis of Maleimide Glycine (Mal-Gly-OH)
Glycine (5 g, 66.6 mmol) and maleic anhydride (6.6 g, 66.6 mmol) were suspended in 80 ml of acetic acid and allowed to react for 3 hrs at RT. The resulting white precipitate was collected by filtration, washed with cold water, and dried (10.95 g, 63.3 mmol, 95%, M.P. 187-189° C., TLC: 2:1:1:1 isopropyl alcohol/acetic acid/ethyl acetate/water, Rf=0.5). The glycine maleic acid intermediate was characterized by proton NMR (300 MHz, DMSO-d6): δ=9.2 (s, 1H) 6.397 (d, 1H, j=8.57 Hz), 6.310 (d, 2H, j=12.86 Hz), 2.0 (d, 2H j=6.86 Hz).
Glycine maleamic acid (5.2 g, 30.04 mmol) and 2.1 equivalents of triethylamine (6.37 g, 63 mmol) were refluxed for 3 hrs in 500 ml toluene with removal of water with a Dean-Stark apparatus. Upon reaction completion, the toluene solution was decanted and dried. The resulting solid was acidified with 2 M HCl, extracted with ethyl acetate, dried with MgSO4 and evaporated to yield Mal-Gly-OH (1.7 g, 11 mmol, 36.5%, MP 99-110° C., TLC: 2:1:1:1 isopropyl alcohol/acetic acid/ethyl acetate/water, Rf=0.72). The product was characterized by proton NMR (300 MHz, DMSO-d6): δ=7.108 (s, 2H), 4.105 (s, 2H).
Synthesis and Characterization of Polyacridine-Melittin Analogues
Melittin analogues, polyacridine peptides, and control peptides were prepared by solid phase peptide synthesis using standard Fmoc procedures with 9-hydroxybenzotriazole and HBTU double couplings on a 30 μmol scale on an Advanced ChemTech APEX 396 synthesizer. Mal-melittin (SEQ ID NO: 67) was prepared by coupling Mal-Gly-OH to the N-terminus of side-chain protected full-length melittin on resin utilizing a 6-fold excess of Mal-Gly-OH, DIC and HOBt, reacted for 4 hrs while stirring. The resin was filtered, washed with DMF, DCM and methanol, and then dried. Peptides were removed from resin and side chain deprotected using a cleavage cocktail of TFA/triisoproylsilane/water (95:2.5:2.5 v/v/v) for 3 hrs followed by precipitation in cold ether. Precipitates were centrifuged for 10 min at 4000 rpm at 4° C. and the supernatant decanted. Peptides were then reconstituted with 0.1 v/v % TFA and purified to homogeneity on RP-HPLC by injecting 0.5-2 μmol onto a Vydac C18 semipreparative column (2×25 cm) eluted at 10 ml/min with 0.1 v/v % TFA with an acetonitrile gradient of 20-45 v/v % over 30 min while monitoring tryptophan (Abs 280 nm) or acridine (Abs 409 nm). The major peak was collected and pooled from multiple runs, concentrated by rotary evaporation, lyophilized, and stored at −20° C. Purified peptides were reconstituted in 0.1% v/v TFA and quantified by absorbance (tryptophan ε280 nm=5600 M−1 cm−1, thiolpyridine and tryptophan ε280 nm=10915 M−1 cm−1, or acridine ε409 nm=9266 M−1 cm−1) to determine isolated yield. Purified peptides were characterized by LC-MS by injecting 2 nmol onto a Vydac C18 analytical column (0.47×25 cm) eluted at 0.7 ml/min with 0.1 v/v % TFA and an acetonitrile gradient of 10-55 v/v % over 30 min while acquiring ESI-MS in the positive ion mode.
Cys-melittin (SEQ ID NO: 52) was reacted with 10-eq of DTDP in 2-propanol/2 N Acetic Acid (10:3) for 8 hrs at RT to generate the thiolpyridine protected peptide. The reaction mixture was concentrated by rotary evaporation and applied to a Sephadex G-10 column eluted (2.5×50 cm) with 0.1 v/v TFA while monitoring absorbance at 280 nm to remove excess DTDP. The peptide peak fractions were pooled, concentrated, lyophilized, and purified to homogeneity by RP-HPLC as described previously.
Poly(Acr-X)n-SS-melittin and poly(Acr-X)n-Mal-melittin peptides were synthesized on a 2 μmol scale based on melittin, using 1.7 equivalents (3.4 μmol) of the reduced poly(Acr-X)n-Cys, where X equals Arg, Lys, or Leu. Mal-melittin (SEQ ID NO: 67) (2 μmol) was prepared in 8 ml of 10 mM ammonium acetate pH 5 and added to poly(Acr-X)n-Cys and 2 ml of methanol to facilitate solubility. The reaction occurred over 12 hrs at RT as determined by analyzing aliquots by LC-MS. At completion the reaction mixture was concentrated by rotary evaporation and lyophilized prior to purification of poly(Acr-X)n-Mal-melittin by RP-HPLC eluted with 0.1 v/v % TFA and acetonitrile gradient (35-45% over 30 min) while detecting at 409 nm.
Alternatively, thiolpyridine-Cys-melittin (2 μmol) was prepared in 8 ml of 10 mM ammonium acetate pH 6 and added to 3.4 vμmol poly(Acr-X)n-Cys in 2 ml of methanol. After 24 hrs, poly(Acr-X)n-SS-melittin was purified and characterized by LC-MS as described above.
Polyacridine-Melittin Hemolysis Assay
Whole blood was obtained from male ICR mice by heart puncture with heparinized 22 G needles and collected in conical tubes containing 10 ml of 0.15 M PBS (pH 7.4) prewarmed to 37° C. Erythrocytes were immediately separated from plasma by centrifugation at 2000 rpm for 2 min, washed three times with 10 ml of PBS, and then diluted to 1.5×108 cells/ml. Peptides were prepared at 15 μM and serially diluted to 10-0.01 μM, after which 100 μl was pipetted in triplicate into a MultiScreenHTS BV 96 well plate. Erythrocytes (50 μl, 7.5×106 cells) were added to the peptides and incubated at 37° C. for 1 h followed by filtration on a Multiscreen vacuum manifold (Millipore Corporation, Billerica, Mass.). The filtrate was measured for Abs410nm on a Biotech plate reader (Biotech Instruments Incorporated., Winooski, Vt.) and compared to the 100% hemolysis caused by replacing PBS with water. Peptide DNA polyplexes (1.5 nmols and 7.5 μg pGL3) were also assayed for hemolysis as described above.
Formulation and Characterization of Polyacridine-Melittin Polyplexes
The relative binding affinity of peptides for DNA was determined by a fluorophore exclusion assay (Rich, D. H., Gesellchen, P. D., Tong, A., Cheung, A., and Buckner, C. K. (1975) Alkylating derivatives of amino acids and peptides. Synthesis of N-maleoylamino acids, [1-(N-maleoylglycyl)cysteinyl]oxytocin, and [1-(N-maleoyl-11-aminoundecanoyl)cysteinyl]oxytocin. Effects on vasopressin-stimulated water loss from isolated toad bladder. J. Med. Chem. 18, 1004-1010). pGL3 (200 μl of 4 μg/ml in 5 mM Hepes pH 7.5 containing 0.1 μM thiazole orange) was combined with 0, 0.05, 0.1, 0.25, 0.35, 0.5, 1, and 2 nmols of peptide in 300 μl of Hepes and allowed to bind at RT for 30 min. Thiazole orange fluorescence was measured using an LS50B fluorometer (Perkin-Elmer, U.K.) by exciting at 498 nm while monitoring emission at 546 nm with the slit widths set at 10 nm. A fluorescence blank of thiazole orange in the absence of DNA was subtracted from all values before data analysis. The data is presented as nmol of peptide per μg of DNA versus the percent fluorescence intensity±the standard deviation determined by three independent measurements.
Particle size and zeta potential were determined by preparing 2 ml of polyplex in 5 mM Hepes pH 7.5 at a DNA concentration of 30 μg/ml with 15 nmols/ml of peptide (0.5 nmol of peptide per μg of DNA). Particle size was measured by quasi-elastic light scattering (QELS) at a scatter angle of 90° on a Brookhaven ZetaPlus particle sizer (Brookhaven Instruments Corporation, NY). The zeta potential was determined as the mean of ten measurements immediately following acquisition of the particle size.
Polyacridine-melittin DNA polyplexes were prepared at 0.5 nmol of peptide per μg of DNA at a concentration of 100 μg per ml of DNA and directly deposited on a freshly cleaved mica surface and allowed to bind for 10 min prior to washing with deionized water. Alternatively, naked DNA (100 μg pGL3 per ml) was prepared in 10 mM Tris, 1 mM EDTA pH 8, then diluted to 1 μg per ml in 40 mM Hepes 5 mM nickel chloride pH 6.7, and deposited on a fresh cleaved mica surface for 10 min followed by washing with deionized water. An Asylum atomic force microscope (AFM) MFP3D (Santa Barbara, Calif.) was operated in the AC-mode in order to image either naked DNA or DNA polyplexes using a silicon cantilever (Ultrasharp NSC15/AIBS, MikroMasch).
Polyacridine-Melittin Polyplex Toxicity
The in vitro toxicity of polyacridine-melittin polyplexes was evaluated by MTT assay (Wadhwa, M. S., Collard, W. T., Adami, R. C., McKenzie, D. L., and Rice, K. G. (1997) Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconjugate Chemistry 8, 81-8). CHO, HepG2 and 3T3 cells were plated on 6×35 mm wells at 5×105 cells/well and grown to 40-70% confluency. The media was replaced with 2 ml of fresh MEM supplemented with 2% FBS, and the cells treated with 0.5 nmol peptide/μg DNA polyplexes. After 6 hrs, the media was replaced with fresh culture media and grown an additional 18 hrs. The media was replaced with 2 ml of fresh media and 500 μL of 0.5% (w/v) 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) in PBS solution and allowed to incubate at 37° C. for 1 hr to let formazan crystals form. The media containing MTT was removed, and the crystals dissolved by the addition of 2 mL of dimethyl sulfoxide (DMSO) and 250 μL Sorenson's Glycine Buffer, then measured by absorbance 595 nm on a microplate reader. The percent viability was determined relative to untreated cells.
In Vitro Gene Transfer of Polyacridine-Melittin DNA Polyplexes
HepG2 cells (5×105) were plated on 6×35 mm wells and grown to approximately 50% confluency. Transfections were performed in MEM supplemented with 2% FBS, sodium pyruvate (1 mM), and penicillin and streptomycin (100 U and 100 μg/mL). Polyplexes were prepared at a DNA concentration of 30 μg/ml and a stoichiometry of 0.5 nmol peptide per μg of DNA in Hepes buffered mannitol (HBM). Polyplexes (10 μg of DNA in 0.3 ml of HBM) were added drop wise to wells in triplicate. After 24 hrs, the cells were washed twice with 2 ml of ice-cold phosphate-buffered saline (Ca2+- and Mg2+-free) and then treated with 0.5 ml of lysis buffer (25 mM Tris Chloride, pH 7.8, 1 mM EDTA, 8 mM magnesium chloride, and 1% Triton X-100) for 10 min at 4° C. Cell lysates were scraped, transferred to 1.5 mL microcentrifuge tubes, and centrifuged for 10 min at 13,000 g at 4° C. to pellet cell debris. Lysis buffer (300 μL), sodium-ATP (4.3 μL of a 165 mM solution at pH 7, 4° C.) were combined in a test tube, mixed briefly, and immediately placed in the luminometer. Luciferase relative light units were measured by a Lumat LB 9501 (Berthold Systems, Germany) with 10 s integration after automatic injection of 100 μL of 0.5 mM D-luciferin. The relative light units were converted to fmol using a standard curve generated by adding a known amount of luciferase to 35 mm wells containing 50% confluent HepG2 cells. The resulting standard curve had an average slope of 2.6×104 relative light units/fmol enzyme. Protein concentrations were measured by a BCA assay using bovine serum albumin as a standard. The amount of luciferase recovered in each sample was normalized to mg of protein and reported as the mean and standard deviation obtained from triplicate transfections. PEI pGL3 polyplexes were prepared by mixing 35 μg of DNA in 525 μL of HBM with 43.8 μg PEI in 525 μL of HBM while vortexing to create DNA complexes possessing a charge ratio (NH4+/PO4−) of 9:1. Cells were transfected with 10 μg PEI-DNA polyplexes as previously described. CHO and 3T3 (5×105) cells were plated on 6×35 mm wells and grown to ca. 50% confluency and then transfected as described above.
Results
Synthetic Strategy for Polyacridine-Melittin
Naturally occurring melittin isolated from bee venom is a 26 amino acid peptide amide composed of two a-helices conjoined through an interrupting proline. Numerous studies have been conducted to investigate the mechanism and sequence specificity of melittin's membrane lytic activity.
Natural melittin contains a single aromatic Trp at residue 8 and does not contain a Cys residue. To improve the synthesis of polyacridine-melittin, we replaced Trp 8 with Leu, and reinstalled a single Trp near the N-terminus in Cys-Trp-Lys-Lys (SEQ ID NO: 51). The reactivity of the Cys residue was increased by flanking Lys residues. This also allowed selective chromatographic detection of full length melittin at 280 nm. These modifications resulted in a Cys-melittin analogue: CWKKGIGAVLKVLTTGLPALISLIKRKRQQ (SEQ ID NO: 52), that SOPMA analysis predicted to maintain a-helical character. A similar Mal-melittin analogue (Mal-GWKKGIGAVLKVLTTGLPALISLIKRKRQQ (SEQ ID NO: 67)), possessing an N-terminal maleimide-glycine (Mal-G) in place of Cys, was also prepared.
Polyacridine and melittin peptides were synthesized using HBTU/HOBt with increased coupling efficiency compared to DIC. Early attempts to synthesize polyacridine peptides using DIC resulted in heterogeneous mixtures of truncated peptides with minimal recovery of full length peptide. The identity of the spacing amino acid between Lys-acridine residues significantly influenced the synthetic yield. Bulky amino acid side chains and protecting groups such as Lys-Boc, Phe-Trt, Leu, Glu-OBut and Arg-Pbf were well tolerated, whereas Gly surprisingly was not. Polyacridine peptides possess a C-terminal Cys to accommodate bioconjugation to Cys-melittin (SEQ ID NO: 52) or Mal-melittin (SEQ ID NO: 67). Polyacridine peptides possessing an alternating Lys-Acr (Acr) spaced by either Arg, Lys, or Leu were designed to influence the charge character of the anchor peptide (Scheme 1).
The length of polyacridine peptides was systematically varied to possess 2-4 Acr-Arg repeats to examine the influence of affinity. Polyacridine nona peptides were routinely obtained in 30-35% purified yield with >95% purity. Polyacridine-melittin peptides were designed to possess either a reducible dithiol or a non-reducible maleimide linkage (Scheme 1). The most expedient synthetic route proved to be cleaveage of Cys-melittin (SEQ ID NO: 52) from the resin, followed by modification with dithiol dipyridine to produce a thiolpyr-melittin (SEQ ID NO: 75). The RP-HPLC monitoring of the reaction of thiolpyr-melittin (SEQ ID NO: 75) with poly(Acr-Arg)4-Cys (SEQ ID NO: 11) is illustrated in
Poly(Acr-X)4-Mal-melittin peptides, where X is Lys (SEQ ID NOS 71 & 67, respectively) or Leu (SEQ ID NOS 72 & 67, respectively), were synthesized to compare their gene transfer properties with poly(Acr-Arg)4-SS-melittin (SEQ ID NO: 78). The synthetic strategy utilized Gly-maleimide that was coupled to the N-terminus of the fully protected melittin peptide on resin (Scheme 1). On work-up this yielded Mal-melittin (SEQ ID NO: 67) that was then directly conjugated to poly(Acr-X)n-Cys peptides. The conjugation of Mal-melittin (SEQ ID NO: 67) with poly(Acr-Arg)4-Cys (SEQ ID NO: 11) was monitored by RP-HPLC resulting in the complete consumption of Mal-melittin (SEQ ID NO: 67) and the formation of poly(Acr-Arg)4-Mal-melittin (SEQ ID NOS 11 & 67, respectively). Purification of poly(Acr-Arg)4-Mal-melittin (SEQ ID NOS 11 & 67, respectively) was achieved with a final yield of 35% and >95% purity. Reducible and non-reducible polyacridine-melittin peptides with Acr-Arg repeat of 2 and 3 were synthesized with similar yield and purity, and characterized by LC-MS (Table 1).
aCalculated and observed mass as determined by ESI LC-MS.
bRBC hemolysis at pH 7.4 and 5.0.
cN.D. = not determined
Physical Properties of Polyacridine-Melittin DNA Polyplexes
The binding of polyacridine-melittin peptides to pGL3 was investigated using a thiazole orange exclusion assay (Rich, D. H., Geselichen, P. D., Tong, A., Cheung, A., and Buckner, C. K. (1975) Alkylating derivatives of amino acids and peptides. Synthesis of N-maleoylamino acids, [1-(N-maleoylglycyl)cysteinyl]oxytocin, and [1-(N-maleoyl-11-aminoundecanoyl)cysteinyl]oxytocin. Effects on vasopressin-stimulated water loss from isolated toad bladder. J. Med. Chem. 18, 1004-1010). Polyacridine-melittin peptides were found to compete for intercalation and displace thiazole orange resulting in a decrease in fluorescence intensity. When titrated at increasing concentration the fluorescence decreased until an asymptote is reached at an equivalence point (
Comparison of poly(Acr-Arg)2-4-SS-melittin (SEQ ID NOS 76-78, respectively) demonstrated nearly equivalent affinity for Acr-Arg repeats of 3 and 4, but less affinity afforded for a repeat of 2 (
The particle size and zeta potential of polyacridine-melittin polyplexes were determined by QELS analysis (Table 2).
aMean particle size of peptide-DNA polyplex (0.5 nmol of peptide per μg of DNA) as determined by QELS.
bMean zeta potential determined in 5 mM Hepes, pH 7.4.
cPercent viability of peptide-DNA polyplexes determined by MTT assay in CHO cells (0.5 nmol of peptide per μg DNA) at 10 μg DNA dose applied to 5 × 105 cells for 6 hours. Nearly identical results were obtained for HepG2 and 3T3 cells.
Poly(Acr-Arg)4-SS-melittin (SEQ ID NO: 78) and poly(Acr-Arg)4-Mal-melittin (SEQ ID NOS 11 & 67, respectively) produced polyplexes of 79-84 nm average diameter, respectively. Comparison of the size of polyplexes prepared with poly(Acr-Arg)3-SS-melittin (SEQ ID NO: 77) (126 nm) and poly(Acr-Arg)2-SS-melittin (SEQ ID NO: 76) (737 nm) established that shorter repeats produced larger particle size (Table 2). This result is consistent with earlier findings that indicated that shorter, low affinity polylysine peptides (<13 residues) (SEQ ID NO: 84) produced larger polyplexes, whereas polylysine of 18 repeats or longer (SEQ ID NO: 85) produced polyplexes of approximately 80 nm in diameter.
Substitution of the spacing Arg for Lys or Leu in Acr-Arg repeats resulted in a minimal change in particle size (Table 2). This supports the hypothesis that polyintercalation, and not ionic binding, is primarily responsible for the binding affinity to DNA. To test this hypothesis, an analogue was prepared that replaced the acridine modified Lys with an acetyl on the s-amine of lysine resulting in poly(Lys(Ac)-Arg)4-SS-melittin (SEQ ID NO: 79). This analogue produced polyplexes of average diameter of 177 nm, suggesting a significantly lower affinity (Table 2).
To further validate the change in particle size determined by QELS, polyplexes were analyzed by atomic force microscopy (AFM). Analysis of pGL3 by AFM demonstrated an open structure occupying from 0.5-1 μm with no single morphology (
Biological Activity of Polyacridine-Melittin DNA Polyplexes
The membrane lytic potency of polyacridine-melittin peptides were investigated using a RBC hemolysis assay (Chen, C.-P., Kim, J.-S., Steenblock, E., Liu, D., and Rice, K. G. (2006) Gene transfer with poly-melittin peptides. Bioconjugate Chemistry 17, 1057-62). As anticipated, poly(Acr-X)4-Cys (SEQ ID NO: 88) anchor peptides alone were inactive in membrane lysis. Alternatively, modification of the N-terminus of natural melittin with Cys-Trp-Lys-Lys (SEQ ID NO: 51) and substitution of Leu for Trp 8 to generate Cys-melittin (SEQ ID NO: 52), resulted in retention of RBC hemolytic (HL50) potency at pH 7.4 relative to natural melittin (
The hemolytic potency of polyacridine melittin peptides was also determined at pH 5 to simulate the pH of the endosome. In contrast to an earlier finding that C and N-terminal modification of natural melittin with Cys-(Lys)4 (SEQ ID NO: 86) resulted in the complete loss of hemolytic activity at pH 5, Cys-melittin (SEQ ID NO: 52) possessed an improved pH 5 RBC lytic potency relative to that of natural melittin (
To establish a relationship between peptide anchor length, reducibility, and peptide DNA stoichiometry, CHO cells were transfected with polyplexes formed with poly(Acr-Arg)2-SS-melittin (SEQ ID NO: 76), poly(Acr-Arg)3-SS-melittin (SEQ ID NO: 77), poly(Acr-Arg)4-SS-melittin (SEQ ID NO: 78), and poly(Acr-Arg)4-Mal-melittin (SEQ ID NOS 11 & 67, respectively) while varying the peptide to DNA ratio from 0.1, 0.35, 0.5, and 0.75 nmols of peptide per μg of DNA (
A broader panel of polyacridine-melittin peptides were combined with pGL3 at a fixed stoichiometry of 0.5 nmol per μg of pGL3 and used to mediate gene expression in HepG2, 3T3, and CHO cells. As illustrated in
To establish the contribution of poly-acridine to DNA binding affinity and gene transfer, the ε-amine of lysine was modified with an acetyl group to prepare poly(Lys(Ac)-Arg)4-SS-melittin (SEQ ID NO: 79). Gene transfer mediated by poly(Lys(Ac)-Arg)4-SS-melittin (SEQ ID NO: 79) was approximately 100-1000 fold less relative to poly(Acr-Arg)4-SS-melittin (SEQ ID NO: 78) in all three cell lines (
The toxicity of polyacridine DNA polyplexes was assessed by MTT assay on CHO, HepG2 and 3T3 cells (Table 2). Poly(Acr-Arg)2-3-SS-melittin (SEQ ID NOS 76 & 77, respectively) DNA polyplexes display no toxicity relative to control. However, poly(Acr-Arg)4-SS-melittin (SEQ ID NO: 78) and poly(Acr-Arg)4-Mal-melittin polyplexes (SEQ ID NOS 11 & 67, respectively) resulted in 70% cell viability while poly(Lys(Ac)-Arg)4-SS-melittin polyplex (SEQ ID NO: 79) was more toxic producing 55% viability. CHO cells treated with poly(Acr-Lys)4-SS-melittin (SEQ ID NO: 80) and poly(Acr-Lys)4-Mal-melittin polyplexes (SEQ ID NOS 71 & 67, respectively) were 75-86% viable, respectively. Whereas, poly(Acr-Leu)4-SS-melittin polyplexes (SEQ ID NO: 81) were compared to poly(Acr-Leu)4-Mal-melittin polyplexes (SEQ ID NOS 72 & 67, respectively) that were minimally toxic (Table 2).
Discussion
The endosome has been proposed as one of the major barriers that limits the gene transfer efficiency of non-viral gene delivery systems. To increase the endosomal escape of plasmid DNA, many prior studies have incorporated fusogenic peptides into experimental delivery systems. Most often, a fusogenic peptide is linked to a PEI or polylysine to allow for multivalent reversible ionic binding with the phosphate backbone of DNA. While this approach often leads to significant increases in gene transfer efficiency in vitro, ionic interactions are relatively weak leading to premature dissociation of the carrier in vivo and degradation of the DNA. To overcome weak binding, higher molecular weight polycations are used. These can be prepared with reducible linkages that revert to low molecular weight, lower affinity polycations and trigger the release of DNA inside the cell. However, despite numerous attempts, i.v. dosed polycationic DNA polyplexes are unable to produce therapeutic levels of gene expression.
We have therefore explored an alternative method of binding fusogenic peptides to plasmid DNA by reversible intercalation. Preliminary studies suggested that a single acridine binds to DNA through intercalation but with relatively weak affinity. Consequently, we sought to increase the binding affinity by preparing polyacridines. Considering the pioneering studies of Szoka who developed a synthetic scheme to prepare a diacridine glycopeptide (Haensler, J., and Szoka, J. F. C. (1993) Synthesis and characterization of a trigalactosylated bisacridine compound to target DNA to hepatocytes. Bioconjugate Chemistry 4, 85-93), and Nielsen who prepared and tested di and triacridine nuclear localization peptides (Shiraishi, T., Hamzavi, R., and Nielsen, P. E. (2005) Targeted Delivery of Plasmid DNA into the Nucleus of Cells via Nuclear Localization Signal Peptide Conjugated to DNA Intercalating Bis- and Trisacridines Bioconjugate Chemistry 16, 1112-1116), we sought a simplified approach that would allow us to extend the valency of polyacridine to four or more acridine units and control the charge of polyacridine DNA polyplexes. We therefore adopted a strategy reported by Ueyama et al. (Ueyama, H., Takagi, M., Waki, M., and Takenaka, S. (2001) DNA binding behavior of peptides carrying acridinyl units: First example of effective poly-intercalation. Nucleic Acids Symp Ser (Oxf) 1, 163-164), who demonstrated that polyacridine peptides could be prepared from Fmoc-Lys(Acr) using solid phase synthesis. Several early attempts at synthesis established that polyacridine peptides could be prepared in good yield (>30%) provided that coupling was conducted with HBTU and that a spacing amino acid was used that had a bulky side chain or protecting group. Using Gly as a spacing amino acid resulted in poor yields.
The synthetic design of polyacridine peptides took into account the relative DNA binding affinity by varying polyacridine repeat, the influence of the spacing amino acid on gene transfer, and linkage between polyacridine and a melittin fusogenic peptide. As indicated in FIGS. 5 and 6A-6C, there is a strong dependency on the nature of the linkage between polyacridine and melittin in relationship to the gene transfer efficiency. A reducible disulfide bond provided a means for the triggered release of melittin either at or inside the cell. The reduction of the disulfide bond greatly diminishes the affinity of melittin for DNA, releasing it and unmasking its membrane lytic activity (
The length of the polyacridine repeat appears to be less important for in vitro gene transfer, since repeats of 2, 3 and 4 poly(Acr-Arg)-SS-melittin (SEQ ID NOS 76-78, respectively) all produced nearly equivalent gene transfer in three cell lines (
The spacing amino acid of Arg, Lys or Leu within a poly(Acr-X)4-SS-melittin (SEQ ID NOS 78, 80, and 81, respectively) only slightly influences their affinity for binding DNA (
The lytic potency of melittin on cells in culture has been well documented. However, this toxicity can be overcome by polymerization of melittin through disulfide bonds resulting in its neutralization due to high affinity binding to DNA. It is apparent that even dimeric-melittin (Core sequence disclosed as SEQ ID NO: 74) can bind to DNA and mediate moderate gene transfer (
In conclusion, we have described a new polyacridine DNA binding anchor that, when linked with melittin through disulfide bond, produces potent in vitro gene transfer. The polyacridine anchor is designed to be optimized for either in vitro or in vivo gene transfer by controlling the binding affinity to DNA and charge of resulting DNA polyplexes. Furthermore, the Cys residue allows coupling of fusogenic peptides, ligands and PEG. These attributes should allow polyacridine several unique advantages compared to other polycationic DNA binding peptides and polymers.
Cationic condensing peptides and polymers bind electrostatically to DNA to form cationic polyplexes. While many cationic polyplexes are able to achieve in vitro transfection mediated through electrostatic interactions, few have been able to mediate gene transfer in vivo. The present study describes the development and testing of polyacridine PEG-peptides that bind to plasmid DNA by intercalation resulting in electronegative open polyplex DNA. (Fernandez, C. A, Baumhover, N. J., Anderson, K., and Rice, K. G. “Discovery of Metabolically Stabilized Electronegative Polyacridine-PEG Peptide DNA Open Polyplexes” Bioconjugate Chemistry (2010) 21, 723-30.) Polyacridine PEG-peptides were prepared by chemically conjugating 6-(9-acridinylamino) hexanoic acid onto side chains of Lys in PEG-Cys-Trp-(Lys)3, 4, or 5 (SEQ ID NOS 17-19, respectively). The resulting PEG-Cys-Trp-(Lys-(Acr))3, 4, or 5 peptides (SEQ ID NOS 3-5, respectively) bound tightly to DNA by polyintercalation, rather than electrostatic binding. Unlike polycationic polyplexes, polyacridine PEG-peptide polyplexes were anionic and open coiled, as revealed by zeta potential and atomic force microscopy. PEG-Cys-Trp-(Lys-(Acr))5 (SEQ ID NO: 5) showed the highest DNA binding affinity and the greatest ability to protect DNA from metabolism by DNase. Polyacridine PEG-peptide DNA open polyplexes were dosed intramuscularly and electroporated in mice to demonstrate their functional activity in gene transfer. These results establish polyacridine PEG-peptide DNA open polyplexes as a novel gene delivery method for in vivo use.
Nonviral gene delivery systems have traditionally relied on reversible binding between cationic carriers and anionic oligonucleotides. The resulting lipoplexes and polyplexes typically possess a positive surface charge as determined by zeta potential measurements. While cationic DNA lipoplexes and polyplexes have shown the ability to mediate in vitro gene transfer through electrostatic binding to cell surfaces, they exhibit poor gene transfer properties in vivo, in part due to their overall cationic charge. There have been many attempts to mask the positive charge of cationic polyplexes with polyethylene glycol (PEG) to improve blood compatibility.
Alternatively, it is difficult to prepare an electronegative DNA polyplex using cationic polymers. This has been attempted by either partially titrating a polycationic polymer with plasmid DNA or by using a layer-by-layer addition of oppositely charge polymers in an attempt to reverse the charge of polyplexes. The resulting electronegative polyplexes are formed in a delicate and unstable equilibrium. Attempting to reverse the charge of a cationic polyplex with the addition of an anionic polymer can lead to dissociation of the DNA. Similarly, if titrated to below the charge equivalency point, the polyplex is not completely protected against DNase, whereas if titrated to charge equivalency, the resulting neutral polyplexes are hydrophobic and aggregate. Titration past the equivalency point, results in collapse of a polyplex into a cationic colloidal particle that is relatively stable but highly cationic and thereby less compatible with blood components. Consequently, we sought to find an alternative approach to ionic binding to DNA that would result in stable electronegative polyplexes.
In principle, the high affinity DNA binding achieved by polyintercalation could result in metabolically stable electronegative polyplexes. Electronegative polyplexes may bind to fewer proteins and thereby be more blood and tissue compatible to allow delivery via intramuscle electroporation (IM-EP).
Polyacridine containing polymers have been previously investigated as gene transfer agents by Szoka, Vierling and Neilsen. Their studies utilized polyacridine polymers possessing either one, two or three acridine units conjugated to either a neoglycopeptide or a nuclear localizing sequence. While these polyacridine carriers could bind to DNA, they possessed modest gene transfer activity in vitro. Alternatively, we have recently reported that a polyacridine peptide modified with a melittin fusogenic peptide is a potent in vitro gene transfer agent as described in Example 1 above. The most potent polyacridine-melittin gene delivery peptide contained four acridines and possessed a sequence of Lys(Acr)-Arg-Lys(Acr)-Arg-Lys(Acr)-Arg-Lys(Acr)-Arg-Cys (SEQ ID NO: 87) joined to melittin by a disulfide bond. Polyacridine-melittin bioconjugates formed electropositive DNA polyplexes in which their potency was dependent upon the number of acridines, the identity of the spacing amino acid, and the presence of a reducible disulfide bond between polyacridine and melittin.
To date, there are no reports of polyacridine peptides modified with PEG. The present study demonstrates a synthetic strategy to modify the side chains of Lys in PEG-Cys-Trp-(Lys)n peptides with acridine. The resulting PEG-Cys-Trp-(Lys(Acr))n peptides bind reversibly to DNA through intercalation and demonstrate the ability to form a unique electronegative open polyplex DNA structure that is protected from DNase and maintains transfection competency in vivo. The unique properties of PEGylated polyacridine DNA electronegative open polyplexes afford desirable characteristics that are more compatible with in vivo nonviral gene delivery compared to cationic polyplexes.
Materials and Methods
N-terminal Fmoc protected amino acids, 9-hydroxybenzotriazole (HOBt), diisopropylcarbodiimide (DIC), and Wang resin were purchased from Advanced ChemTech (Lexington, Ky.). Sephadex G-25, HEPES buffer, tris(2-carboxyethyl)-phosphine hydrochloride (TCEP), diisopropylethylamine (DIPEA), piperidine, acetic anhydride, triisopropylsilane (TIS), DNase I (EC 3.1.21.1), 9-chloroacridine, and thiazole orange were obtained from Sigma Chemical Co (St. Louis, Mo.). Acetonitrile, N,N-Dimethylformamide (DMF), and trifluoroacetic acid (TFA) were purchased from Fisher Scientific (Pittsburgh, Pa.). Agarose was obtained from Gibco-BRL. mPEG-maleimide 5000 Da was purchased from Nektar (Huntsville, Ala.), mPEG-amine (5,000 Da) was purchased from Creative Biotechnology (Winston-Salem, N.C.), and bis-amino PEG (2,000 Da) was purchased from Iris Biotech GmbH (Marktredwitz, Germany). The 5.3 kb luciferase plasmid, pGL3 control vector, containing a SV40 promoter and enhancer was obtained from Promega (Madison, Wis.). Plasmid DNA was amplified in DH5α strain of E. coli and purified according to the manufacturer's instructions.
Synthesis and Characterization of PEGylated Cys-Trp-Lyse Peptides
Cys-Trp-Lysn synthesis was carried out using standard Fmoc chemistry on a computer interfaced Advanced Chemtech APEX 396 solid phase peptide synthesizer with 9-hydroxybenzotriazole and diisopropylcarbodiimide double couplings followed by N-capping with acetic anhydride as described previously(Chen, C. P., Park, Y., and Rice, K. G. (2004) An improved large-scale synthesis of PEG-peptides for gene delivery. Journal of Peptide Research 64, 237-43). Cleavage and deprotection were accomplished by reacting the resin with TFA:TIS:water (95:2.5:2.5) at RT for 3 hrs. The crude peptide was precipitated in cold diethyl ether, centrifuged, and the supernatant was decanted. Crude peptides were reconstituted in 0.1% TFA and purified on a preparatory RP-HPLC using a Vydac C18 column (2×25 cm) eluted at 10 ml/min with 0.1 v/v % TFA and a gradient of acetonitrile of 5-25% over 30 min while monitoring Abs 280 nm. Purified peptides were reconstituted in 0.1% TFA and quantified by Abs (Trp ε280nm=5600 M−1 cm−1) to determine the isolated yield of 30%. The purified peptides were characterized using LC-MS by separation on a Vydac C18 analytical column (0.47×25 cm) eluted at 0.7 ml/min with 0.1% TFA and a gradient of acetonitrile of 5-25% over 30 min while detecting ESI-MS in the positive ion mode.
PEGylation of the Cys residue on Cys-Trp-Lys3, 4 and 5 (SEQ ID NOS 14-16, respectively) was achieved by reacting 0.9 mol equivalents of peptide with 1 mol equivalent of PEG5000 Da-maleimide in 100 mM sodium phosphate buffer pH 7 for 1 hr at RT. PEGylated peptides were purified on a G-25 column (2.5×50 cm) eluted with 0.1% acetic acid while monitoring Abs 280 nm. The peak corresponding to the PEG-peptide eluted in the void volume (100 ml), was pooled, concentrated by rotary evaporation, and freeze-dried. The PEG-peptide was reconstituted in 0.1% TFA, and quantified by Abs (Trp ε280nm=5600 M−1 cm−1) to determine an isolated yield of 80%. PEG-peptides were characterized by MALDI-TOF MS by combining 1 nmol with a-cyano-4-hydroxycinnamic acid (CHCA) prepared in 50% (v/v) acetonitrile and 0.1% TFA. Samples were spotted onto the target and ionized on a Bruker Biflex III Mass Spectrometer operated in the positive ion mode.
Synthesis of Polyacridine PEG Peptides and Mono and Bis-Acridine PEGs
6-(9-Acridinylamino) hexanoic acid was prepared according to a prior published procedure (Karup, G., Meldal, M., Nielsen, P. E., and Buchardt, 0. (1988) 9-Acridinylpeptides and 9-acridinyl-4-nitrophenylsulfonylpeptides. Synthesis, binding to DNA, and photoinduced DNA cleavage. Int J Pept Protein Res. 32, 331-343). The carboxyl group on 6-(9-acridinylamino) hexanoic acid was activated with 1.1 mol equivalents of DIC and HOBt in DMF. Activated 6-(9-acridinylamino) hexanoic acid (12 mol equivalents) was reacted with 2.5 μmmol of PEG-Cys-Trp-Lys3, 4 and 5 (SEQ ID NOS 17-19, respectively) in 3 ml of DMF at RT for 24 hrs. The PEG-Cys-Trp-(Lys(Acr))3, 4 and 5 peptides (SEQ ID NOS 3-5, respectively) were purified using a G-25 column (2.5×50 cm) eluted with 0.1% acetic acid while monitoring Abs 280 nm. The product peak eluting at 100 ml was pooled, freeze dried, and characterized using MALDI-TOF MS as described above. A yield of 42% of PEG-Cys-Trp-(Lys(Acr))3, 4, and 5 peptides (SEQ ID NOS 3-5, respectively) was determined by acridine Abs (ε409nm=9266 M−1 cm−1) assuming additivity of acridine molar absorptivity and complete conjugation to the ε-amine of Lys. Similarly, mono and bis-acridinylated PEGs were prepared by reacting 6 mol equivalents of activated 6-(9-acridinylamino) hexanoic acid with PEG-amine or bis-amino PEG (2 μmol) in 2 ml of DMF. The acridinylated PEGs were purified by G-25 column and characterized by MALDI-TOF MS.
Thiazole Orange Displacement Assay
The binding of polyacridine PEG-peptides to DNA was determined using an intercalator dye displacement assay (McKenzie, D. L., Kwok, K. Y., and Rice, K. G. (2000) A potent new class of reductively activated peptide gene delivery agents. Journal of Biological Chemistry 275, 9970-9977). pGL3 (1 μg) was prepared in 5 mM Hepes pH 7.4 containing 40 nM thiazole orange. Polyacridine PEG-peptides were added to pGL3 to prepare samples of 0, 0.25, 0.5, 1, 2, 3, and 4 nmol per μg of DNA in a final volume of 500 μL. The fluorescence intensity of each sample was measured using an LS50B fluorometer (Perkin-Elmer, UK) with an excitation wavelength of 500 nm while monitoring emission at 530 nm. The data was converted to percent by comparison to the fluorescence intensity of thiazole orange in buffer (0%) and pGL3 with fully bound thiazole orange (100%).
Gel Band Shift and DNase Protection Assay
pGL3 (1 μg) or DNA polyplexed (1 μg) prepared in 18 μl of normal saline were combined with 1 nmol of either mono-acridine PEG, bis-acridine PEG, PEG-Cys-(Lys-Acr)3 (SEQ ID NO: 20), PEG-Cys-(Lys-Acr)4 (SEQ ID NO: 21), or PEG-Cys-(Lys-Acr)5 (SEQ ID NO: 22) and 2 μl of loading buffer (Adami, R. C., and Rice, K. G. (1999) Metabolic stability of glutaraldehyde cross-linked peptide DNA condensates. Journal of Pharmaceutical Sciences 88, 739-746). The samples were loaded onto a 1% agarose gel (50 ml) and electrophoresed in TAE buffer at 80 V for 90 min. The gel was stained in 2 mg/ml ethidium bromide at 5° C. overnight, and the transilluminated gels were photographed using Polaroid 667 film. pGL3 (1 μg) or DNA polyplexes (1 μg) prepared with 1 nmol of either mono-acridine PEG, bis-acridine PEG, PEG-Cys-(Lys-Acr)3 (SEQ ID NO: 20), PEG-Cys-(Lys-Acr)4 (SEQ ID NO: 21), or PEG-Cys-(Lys-Acr)5 (SEQ ID NO: 22) in 20 μl of normal saline was incubated with 0.06 U of DNase I at 37° C. for 0-20 min. The samples were applied to a 1% agarose gel and electrophoresed as described above.
Particle Size and Zeta Potential of Polyacridine PEG-peptide DNA Open Polyplexes
Polyacridine PEG-peptide DNA polyplexes were formed by combining 10 μg of pGL3 (in 500 μl of 5 mM Hepes pH 7.4) with an equal volume containing either 1, 2, 4, 8, 12, 16, or 20 nmol of polyacridine PEG-peptide while vortexing. The polyplexes were equilibrated at RT for 30 min prior to analysis of particle size (QELS) and zeta potential using a Brookhaven ZetaPlus (Brookhaven Instruments, Holtsville, N.Y.). The particle size diameter and zeta potential are reported as the mean and standard deviation of ten measurements.
Atomic Force Microscopic Analysis of Polyacridine PEG-peptide DNA Open Polyplexes
pGL3 was prepared at a concentration of 100 μg per ml in 10 mM Tris containing 1 mM EDTA pH 8. DNA polyplexes were prepared identically with the addition of PEG-Cys-Trp-(Lys(Acr))5 (SEQ ID NO: 5) at either 0.2 or 1 nmol per μg of DNA. pGL3 and DNA polyplexes were diluted 10-fold in 40 mM Hepes containing 5 mM nickel chloride pH 6.7, then deposited on a fresh cleaved mica surface and incubated for 10 min, followed by washing with deionized water. Alternatively, polyacridine-melittin DNA polyplexes were prepared at 0.5 nmol of peptide per μg of DNA at a concentration of 100 μg per ml of DNA and directly deposited on a freshly cleaved mica surface and allowed to bind for 10 min prior to washing with deionized water. Images were captured using an Asylum atomic force microscope (AFM) MFP3D (Santa Barbara, Calif.) operated in the AC-mode using a silicon cantilever (Ultrasharp NSC15/AIBS, Mikro Masch).
Intramuscle-Electroporation Dosing
Male ICR mice (Harlan), weighing 25-30 g were prepared for IM-EP dosing by anesthetization with an intraperitoneal dose of 200 μl of ketamine/xylazine (20 mg/ml and 2 mg/ml, respectively). The hamstring muscles were sheared and swabbed with 70% ethanol prior to administering a 50 μl dose over 10 sec in normal saline to both gastrocnemius muscles in 2 mice by a 1 ml monoject syringe (1 cc, 28 G×½). After dosing the BTX 2-Needle Array Electrode was inserted into the skin with the electrodes straddling the dosing site. Successive electronic stimulation was generated by the EMC BTX 830, Square-wave Pulse Generator (BTX, Harvard Apparatus) as the power source. At 1 min post-administration of the DNA dose, the pulse generator delivered six successive 100 V pulses over 20 msec with a 100 msec interval between pulses (31).
Bioluminescence Imaging
Luciferase reporter gene expression was quantified by bioluminescence imaging (BLI) at 2-14 days following IM-EP using an IVIS Imaging System 200 Series (Xenogen) (Wu, J. C., Sundaresan, G., Iyer, M., and Gambhir, S. S. (2001) Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Molecular Therapy: the Journal of the American Society of Gene Therapy 4, 297-306). Mice were anesthetized by isofluorane (2% flow with oxygen) and dosed intramuscularly with 40 μL of 30 mg per ml D-Luciferin (GoldBio). Bioluminescent images were acquired 5 min post substrate administration and acquired for 1 min with a 24.6 cm field of view. The resultant grayscale images with a colormap overlay were analyzed using the Igor Pro 4.09 software (Livinglmage). Luciferase expression is reported as photons/sec/cm2/steradian within a uniformly defined region of interest.
Results
Several polyintercalator constructs that bind to double stranded DNA have been reported in prior studies aimed at delivering plasmid DNA (Haensler, J., and Szoka, J. F. C. (1993) Synthesis and characterization of a trigalactosylated bisacridine compound to target DNA to hepatocytes. Bioconjug. Chem. 4, 85-93; Boulanger, C., Di Giorgio, C., and Vierling, P. (2005) Synthesis of acridine-nuclear localization signal (NLS) conjugates and evaluation of their impact on lipoplex and polyplex-based transfection. Eur J Med Chem 40, 1295-306; Shiraishi, T., Hamzavi, R., and Nielsen, P. E. (2005) Targeted Delivery of Plasmid DNA into the Nucleus of Cells via Nuclear Localization Signal Peptide Conjugated to DNA Intercalating Bis- and Trisacridines Bioconjugate Chemistry 16, 1112-1116). These studies designed and tested delivery molecules possessing one-three acridine dyes displayed on a branched polymer modified with a neoglycopeptide or a nuclear localizing peptide, the later of which were shown to mediate in vitro gene expression. These studies established that two to three acridines was required to achieved sufficient DNA binding affinity for in vitro transfection.
In the present study we sought to use a synthetic strategy that would allow for the incorporation of more than three acridines by covalent modification of the side chain of PEGylated polylysine. This was accomplished by first modifying acridine to possess a 6-amino hexanoic acid and then activating the carboxyl group to allow coupling to the ε-amines of PEG-Cys-Trp-(Lys)3, 4 and 5 (SEQ ID NOS 17-19, respectively) to afford PEG-Cys-Trp-(Lys(Acr))3, 4 and 5 (SEQ ID NOS 3-5, respectively) (
Chromatographic evidence supporting the synthesis of PEG-Cys-Trp-(Lys(Acr))5 (SEQ ID NO: 5) is illustrated in
The complete conjugation of acridine to the each Lys side chain was established using MALDI-TOF MS analysis. Conjugation of Cys-Trp-(Lys)5 (SEQ ID NO: 16) (948.8 g/mol) with polydisperse PEG of average mass of 5425 Da results in a PEG-Cys-Trp-(Lys)5 (SEQ ID NO: 19) with an apparent average mass of 6546 Da (
aDetermined by ESI-MS.
bMeasured mean difference in MALDI-TOF mass due to the addition of acridine.
cCalculated number of acridine-6-amino-hexanoic acids based on 291 g/mol.
The relative DNA binding affinity of mono and bis-acridine PEG compared to polyacridine PEG-peptides was established using a thiazole orange displacement assay (
The DNA binding affinity was also compared by a band shift assay performed at a constant stoichiometry of 1 nmol per μg of DNA (
A further demonstration of polyacridine binding to DNA binding utilized a titration experiment while monitoring both the particle size and zeta potential of DNA polyplexes as a function of increasing concentration of polyacridine (
The unusual zeta potential properties of the polyacridine DNA polyplexes prompted an investigation into their morphology using atomic force microscopy. Under analysis by AFM, plasmid DNA is observed as an open circular structure when immobilized onto electropositive mica prepared with immobilized Ni (
We conjectured that the DNA in open polyplexes may be protected from metabolic degradation by serum endonucleases. The metabolic stability was evaluated by treating pGL3 with DNase followed by gel electrophoresis. Unprotected pGL3 is significantly degraded by DNase in 5 min and completely degraded by 10 min (
The in vivo gene transfer properties of PEG-Cys-(Lys-(Acr))5-DNA open polyplexes (SEQ ID NO:22) were evaluated in mice following IM-EP. pGL3 and pGL3 PEG-Cys-(Lys-(Acr))5 (SEQ ID NO: 22) open polyplexes prepared at 0.2, 2, and 4 nmol per μg of DNA formulations were administered by IM-EP and the expression was monitored for two weeks by bioluminescence imaging (
Discussion
An important function of a gene delivery carrier is to protect DNA from premature metabolism during transit. The present study demonstrates that polyintercalation provides strong and reversible binding to DNA that delays metabolic degradation. The main advantage of this approach over polycationic polymer binding to DNA is that high affinity can be achieved with a short polyacridine and that the charge of the resulting DNA polyplexes can be controlled to be either positive or negative, depending on intended applications in vitro or in vivo. Prior reports of the cellular toxicity of known intercalators demonstrate a dependency on both chemical structure and dose (Ferguson, L. R., and Denny, W. A. (2007) Genotoxicity of non-covalent interactions: DNA intercalators. Mutat Res 623, 14-23). Little or no information is available regarding the toxicity of PEGylated polyacridine peptides.
To evaluate the relationship between DNA binding affinity and metabolic stability, five DNA carriers were prepared that varied the number of acridines from 1 to 5. The synthetic strategy conjugated 6-(9-acridinylamino) hexanoic acid with the primary amine(s) on PEG-amine, bis-amino PEG, and the c-amines on PEG-Cys-Trp-(Lys)3, 4 or 5 (SEQ ID NOS 17-19, respectively). This strategy not only simplified the chemical preparation of the delivery molecules, but also allowed for a long 12 atom tether between each acridine and the peptide backbone to facilitate flexible multivalent binding of acridine with DNA.
The DNA binding affinity significantly increased for PEG-Cys-(Lys-(Acr))3, 4, and 5 (SEQ ID NOS 20-22, respectively) compared to mono and bis-acridine PEG as determined by both fluorophore displacement and DNA band shift on agarose gel electrophoresis (
IM-EP of cationic DNA polyplexes results in lower gene expression levels compared to naked DNA alone. This may be due to the charge of cationic polyplexes that are unable to electromigrate through the transient pore formed during electroporation. In contrast, the IM-EP of DNA versus PEG-Cys-(Lys-(Acr))5 (SEQ ID NO: 22) DNA open polyplexes resulted in very similar levels and duration of expression in mice over two weeks. However, at an elevated stoichiometry of PEG-Cys-(Lys-(Acr))5 (SEQ ID NO: 22), a lower but more sustained expression was determined, perhaps due to the metabolic protection afforded by the peptide at higher stoichiometries.
The results of this study establish a new family of PEGylated polyacridine gene delivery carriers that bind to DNA and provide protection against DNase. The unique anionic open polyplex structure is compatible with IM-EP. Given the flexibility of design, polyacridine gene delivery systems could be optimized for a variety of other nonviral gene delivery applications.
Glycosylation is crucial to the propagation of pathogenic viral particles in vivo. Glycosylation masks the agent from immune detection and mediates binding and cellular uptake. The Man9 N-glycan found on the surface of HIV is an example of this type of system. High-mannose N-glycans are found in a variety of plant and animal sources in nature. They bind to a family of calcium dependent receptors present on macrophages and on cells of the immune system. The macrophage mannose receptor binds di-mannose clusters whereas the dendritic cell SIGN receptor recognizes branched high mannose structures.
Similarly, plasmid based DNA vaccines transfect cells more efficiently when a targeting ligand is a component of the vector. To prime the immune system we targeted plasmid DNA into dendritic cells via the mannose binding lectin found on the cell surface. We incorporate a high mannose N-glycan, Man9GlcNAc2, in our vector to stimulate a dendritic cell specific response. (Anderson, K, Fernandez, C. A., and Rice, K. G. “N-Glycan Targeted Gene Delivery to the Dendritic Cell SIGN Receptor” Bioconjugate Chemistry (2010) 21, 1479-85.)
Several attempts have been made toward the synthesis of Man9GlcNAc2. These syntheses are typically long, multi-step procedures and are low yielding. Our approach involves the purification of soybean agglutinin, which is a galactose specific lectin and glycoprotein containing Man9GlcNAc2. A Sepharose N-Caproyl Galactosamine affinity column was constructed and used to isolate SBA in a single chromatographic step from soy flour extract. Affinity purified soybean agglutinin is digested with Pronase to release Man9GlcNAc2-Asn, which is then derivatized with tyrosine and a Maleimide derivative of proprionic acid.
A peptide composed of cysteine, lysine, and lysine derivatized with an intercalating dye was synthesized, and conjugated to the maleimide functionality of Man9GlcNAc2 (Formula IV). CHO cells with a recombinant DC-SIGN receptor and the PGL3 plasmid are part of our in vitro system to measure the targeting and transfection efficiency of our gene delivery vector.
N-Glycan Targeted Gene Delivery to the Dendritic Cell Sign Receptor
A novel non-viral gene delivery vector composed of a high mannose N-glycan conjugated to a polyacridine peptide was prepared. The glycopeptide was designed to bind to plasmid DNA by a combination of polyintercalation and ionic binding, and to the DC-SIGN (Dendritic Cell-Specific Intracellular adhesion molecule-3 Grabbing Non-integrin) receptor expressed on CHO cells by recognition of the high mannose N-glycan. The glycopeptide conjugate was prepared by purification of a high mannose N-glycan from affinity fractionated soybean agglutinin (SBA). The SBA was proteolyzed to release the N-glycan which was then modified on its N-terminus with Tyr and a propionate maleimide. A DNA binding polyacridine peptide, Cys-(Acr-Lys)4 (SEQ ID NO: 23), was prepared by solid phase peptide synthesis using Fmoc-Lys(Acr), then conjugated to the maleimide on the N-glycan to produce a glycopeptide. The glycopeptide bound to DNA with high affinity as determined by fluorophore displacement assay and DNA band shift on agarose gel. When bound to Cy5 labeled DNA, the glycopeptide mediated specific uptake in DC-SIGN CHO (+) cells as determined by FACS analysis. In vitro gene transfer studies established that the glycopeptide increased the specificity of gene transfer in DC-SIGN CHO (+) cells 100-fold relative to CHO (−) cells. These studies suggest that a high-mannose N-glycan conjugated to a polyacridine peptide may also facilitate receptor mediated gene delivery in dendritic cells and thereby find utility in the delivery of DNA vaccines.
Introduction
Dendritic cells (DC) are the primary antigen presenting cells in the immune system, and are therefore central to the development of vaccines. One of the challenges in developing DNA vaccines is the design of vectors that efficiently and selectively target DCs. The DC-SIGN (Dendritic Cell-Specific Intracellular adhesion molecule-3 Grabbing Non-integrin) receptor is a cell surface endocytosing lectin that is specifically expressed on DCs that binds to glycoprotein N-glycans of the high-mannose or complex type possessing terminal LeX with a μM Kd. The receptor is therefore ideally located to facilitate receptor mediated gene delivery to DCs.
Others have targeted either immunogenic proteins or plasmid DNA to internalize into DCs via DC-SIGN in an attempt to prime the immune system. These studies establish that either encapsulation of DNA into mannosylated liposomes or complexation of DNA with mannosylated-PEI, mannosylated-chitosan, mannan-polylysine, or mannosylated glycolipid, results in gene delivery with improved immune response when administered i.m. or i.p. Other studies have determined that high-mannose N-glycans on remodeled glycoproteins are able to target DC-SIGN resulting in uptake into DCs and enhanced immune response. While gene delivery to DCs with mannose containing polymers and liposomes has been achieved, no study has yet demonstrated the delivery of DNA to DCs using a natural high mannose N-glycan.
Reversible binding of an N-glycan to DNA can be accomplished by covalently linking it to a polylysine peptide resulting in cationic polyplex. However, polylysine peptides of 18 residues or longer (SEQ ID NO: 85) are necessary to achieve sufficient affinity to protect DNA, and the resulting electropositive polyplexes bind non-specifically to numerous proteins in vivo. To overcome these limitations, we recently demonstrated that short cationic peptides possessing multiple acridines attached to the side chain of Lys residues bind DNA with much higher affinity and protect DNA from metabolism compared to much longer polylysine peptides.
Functionalized polyacridine peptides, modified with either PEG or a fusogenic peptide, have been shown to mediate gene transfer in vitro or in vivo. Earlier studies have also demonstrated the efficacy of a polyacridine polymer functionalized with either a nuclear localization signal (NLS) or a neoglycopeptide (Shiraishi, T., Hamzavi, R., and Nielsen, P. E. (2005) Targeted Delivery of Plasmid DNA into the Nucleus of Cells via Nuclear Localization Signal Peptide Conjugated to DNA Intercalating Bis- and Trisacridines Bioconjugate Chemistry 16, 1112-1116; Haensler, J., and Szoka, J. F. C. (1993) Synthesis and characterization of a trigalactosylated bisacridine compound to target DNA to hepatocytes. Bioconjug. Chem. 4, 85-93). These experiments demonstrated the importance of increasing the DNA binding affinity by increasing the number of acridines. An early report by Ueyama also demonstrated that polyacridine peptides possessing two to five Lys(Acr) residues results in progressively higher affinity for calf thymus DNA (Ueyama, H., Takagi, M., Waki, M., and Takenaka, S. (2001) DNA binding behavior of peptides carrying acridinyl units: First example of effective poly-intercalation. NUCLEIC ACIDS SYMP SER (OXF) 1, 163-164).
To date, there have been no reports of the successful development and use of a polyacridine glycopeptide in gene transfer. Here, we report the purification of a high-mannose N-glycan from soybean agglutinin and its conjugation to a polyacridine peptide. The resulting glycopeptide binds to plasmid DNA with high affinity and mediates targeted uptake and gene expression in DC-SIGN expressing cells in vitro.
Materials and Methods
Sepharose CL-4B, D-galactosamine HCl, 6-aminocaproic acid, Boc-tyrosine N-hydroxysuccinimide, 9-chloroacridine (97%), pronase, thiazole orange, phenol, super-DHB diisopropylethylamine, piperidine, triisopropylsilane (TIS), polyethylenimine (PEI), and acetic anhydride were from Sigma-Aldrich (St. Louis, Mo.). Sephadex G-50 resin was from Amersham Biosciences (Pittsburgh, Pa.). AG 50W-X2 cation exchange resin was from Bio-Rad (Hercules, Calif.). 1,1′ carbonyldiimidazole, and N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide HCl were Fluka Biochemica products (St. Louis, Mo.). 3-maleimidoproprionic acid N-hydroxysuccinimide ester was from ABD Bioquest, Inc (Sunnyvale, Calif.). NuPAGE® Novex Bis-Tris Gels, Dulbecco's Modified Eagle Medium (DMEM), MEM non-essential amino acids, Dulbecco's phosphate buffered saline (DPBS) and fetal bovine serum (FBS) were from Invitrogen (Carlsbad, Calif.). D2O was from Cambridge Isotope Laboratories (Cambridge, Mass.). Untoasted soy flour was obtained from Archer Daniels Midland (Decatur, Ill.). Sodium hydroxide was a Mallinckrodt product through Fisher Scientific (Pittsburgh, Pa.). Fmoc-Lys-OH was from Novabiochem. Ethidium bromide was from Bio-Rad. Fmoc-Lys(Boc)-Wang resin, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Trt)-OH, N-methyl-2-pyrrolidinone (NMP), O-benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate (HBTU) and hydroxybenzotriazole hydrate (HOBt) were from Advanced ChemTech (Lexington, Ky.). N′,N-dimethylformamide (DMF) was from Amresco (Solon, Ohio). Human DC-SIGN (+) and DC-SIGN (−) CHO cells were a gift from Drs. Chae Gyu Park and Ralph M. Steinman of the Laboratory of Cellular Immunology and Physiology at The Rockefeller University (28). Cy5™ LabelIT was from Mirus Biotechnology (Madison, Wis.). pGL3 control vector, a 5.3 kb luciferase plasmid containing an SV40 promoter and enhancer, was obtained from the Promega corporation (Madison, Wis.), amplified in DH5α E. coli from Invitrogen, and purified with a Giga kit from Qiagen (Valcencia, Calif.). D-Luciferin was from Gold Biotechnology (St. Louis, Mo.), Adenosine 5′-triphosphate was from Roche (Indianapolis, Ind.), and BCA Protein Assay reagents were Pierce protein research products of Thermo Scientific (Rockford, Ill.). All reagents and solvents were certified ACS grade, molecular biology grade, or an equivalent.
Preparation of Sepharose N-Caproylgalactosamine Affinity Resin
6-Aminocaproic acid was coupled to activated Sepharose CL-4B as described (Bethell, G. S., Ayers, J. S., Hancock, W. S., and Hearn, M. T. (1979) A novel method of activation of cross-linked agarose with 1,1′-carbonyldiimidazole which gives a matrix for affinity chromatography devoid of additional charged groups. J Biol Chem 254, 2572-4). Briefly, a moist cake (50 g) of Sepharose CL-4B was activated with 1,1′ carbonyldiimidazole (CDI) (1.2 g). After a 15 min reaction with CDI, the mixture was washed with 1 L of acetone, then reacted with 14 g of 6-aminocaproic acid in 90 ml of water. The pH of the slurry was adjusted to 10 with 1
M sodium hydroxide and stirred overnight at 4° C. Ligand coupling proceeded with the addition of 600 mg of galactosamine and 300 mg of CDI followed by reaction for 2 hrs (Allen, A. K., and Neuberger, A. (1975) A simple method for the preparation of an affinity absorbent for soybean agglutinin using galactosamine and CH-Sepharose. FEBS Letters 50, 362-4). The affinity resin (30 ml) was washed with 90 ml each of 1 M sodium chloride, 1 M sodium chloride in 0.1 M Tris pH 8.6, 1 M sodium chloride in 50 mM sodium formate pH 3.0, 1 M sodium chloride in 0.1 M Tris pH 8.6, water, and PBS.
Purification of Soybean Agglutinin (SBA)
Soy flour (10 g) was dissolved in 200 ml of PBS and stirred overnight at 4° C. The slurry was centrifuged at 9,000×g for 15 min, and the supernatant was applied to the affinity column (2.5×10 cm). The column was washed with 90 ml PBS until the Abs280nm of the effluent was below 0.02 units. The bound SBA was eluted with 90 ml of 0.2 M galactose in PBS (Allen, A. K., and Neuberger, A. (1975) A simple method for the preparation of an affinity absorbent for soybean agglutinin using galactosamine and CH-Sepharose. FEBS Letters 50, 362-4). The SBA was pooled and dialyzed in 12-14 kDa MWCO tubing for 48 hrs against running water and freeze dried.
Purification of Man 9 from SBA
Affinity purified SBA was proteolytically digested to release Man 9 which was then purified following the method of Lis et al. (Lis, H., and Sharon, N. (1978) Soybean Agglutinin—A Plant Glycoprotein. Structure of the Carbohydrate Unit. I Biol. Chem. 253, 3468-3476). Briefly, SBA (600 mg in 8 ml 1 mM hydrochloric acid) was heat denatured at 50° C. for 15 min and digested with 12 mg of pronase for 48 hr at 37° C. The digest was centrifuged at 4,000×g and the supernatant applied to a Sephadex G-50 column (1.5×170 cm) eluted with 10 mM acetic acid. The fractions (8.5 ml) were monitored by Abs 280 nm and an 200 μl aliquot of each fraction was analyzed for carbohydrate by the phenol sulfuric assay (Dubois, M., Gilles, K., Hamilton, J. K., Rebers, P. A., and Smith, F. (1951) A Colorimetric Method for the Determination of Sugars. Nature 168, 167). Carbohydrate containing fractions were pooled, concentrated and re-purified by gel filtration on Sephadex G-50. Man 9 containing fractionations were prepared in 1.5 ml of water then applied to a AG 50W-X2 cation exchange column (1.5×50 cm) eluted with 1.2 L of 1 v/v % pyridine/acetic acid, pH 3.2 while detecting carbohydrate by the phenol-sulfuric assay. The Man 9 containing fractions eluting a 880 ml were pooled and freeze dried. The recovery was estimated by phenol sulfuric assay to be 6.7 μmols (45%) based on 18.5 nmols of Man9GlcNAc2Asn=1 AU490nm.
The purified Man 9 was analyzed by mass spectroscopy by preparing 2 nmol in 4 μl of 10 mM sodium chloride containing 0.5 mM of super 2,5-DHB. The sample was spotted on the target and analyzed by MALDI-TOF (Biflex III, Bruker) in reflectron mode resulting in the detection of masses of 2019.72 and 2041.66 m/z corresponding to [M+Na] and [M+2Na].
Man 9 was analyzed by high field NMR (600 MHz Varian) by preparing a 1 mM sample in D2O with acetone as an internal standard. The chemical shift data corresponded with that published previously (Dorland, L., van Halbeck, H., Vliegenthart, J. F. G., L is, H., and Sharon, N. (1981) Primary Structure of the Carbohydrate Chain of Soybean Agglutinin. A Reinvestigation by High Resolution 1H NMR Spectroscopy. J. Biol. Chem. 256, 7708-7711).
The amino acid peptide, Cys-(Acr-Lys)4 (SEQ ID NO: 23), was synthesized using standard Fmoc chemistry with HOBt and HBTU double coupling on a 30 μmol scale with an APEX 396 solid phase peptide synthesizer using Fmoc-Lys(Acr) prepared as described previously (Tung, C., Zhu, T., Lackland, H., and Stein, S. (1992) An acridine amino acid derivative for use in Fmoc peptide synthesis. Peptide Research 5, 115-8). The peptide was cleaved from the resin and deprotected with 2 ml of TFA/TIS/H2O (95:2.5:2.5 v/v/v) for 3 hr, followed by precipitation in 40 ml of cold ether. The precipitate was collected by centrifugation at 4,000×g for 10 min, and reconstituted in 0.1 v/v % TFA. The peptide was preparatively purified on RP-HPLC by injecting 2 μmols onto a 2×25 cm Vydac C18 column eluted at 10 ml per min with 0.1% TFA and a 15-30% acetonitrile gradient over 45 min while detecting at Abs280nm. The peptide was pooled, concentrated by rotary evaporation, reconstituted in 0.1 v/v % TFA, and then analyzed for purity by RP-HPLC, injecting 5 nmol onto a 0.47×25 cm Vydac C18 column eluted at 1 ml/min with 0.1% TFA and a gradient of 15-30% acetonitrile while detecting by positive mode ESI-MS. The doubly charged ion was detected with an m/z of 928.7, resulting in an observed mass of 1855.4 m/z (calc=1855.5 m/z). The synthesis resulted in a 17% isolated yield (ε409 nm=37, 064 M−1 cm−1) at >95% purity.
Synthesis of a Man 9 Glycopeptide
Man 9 (500 nmol) was prepared in 500 μl of 50 v/v % DMF and 100 mM sodium bicarbonate containing Boc-Tyr-NHS (5 μmol) and reacted for 3 hr at RT. The reaction mixture was directly applied to a Sephadex G-25 column (0.5×50 cm) eluted with 10 mM acetic acid while detecting Abs280nm. The Man 9 Tyr-Boc product peak eluting at 50 ml was concentrated by rotary evaporation and reconstituted in water. The product was analyzed for purity by analytical RP-HPLC eluting at 1 ml per min with 0.1% TFA and a 1-30% gradient of acetonitrile over 30 min while detecting by Abs280nm and by negative mode ESI-MS. The doubly charged ion was detected with an m/z of 1129.4, resulting in a mass of 2260.8 m/z (calculated 2260.0 m/z). The Man 9 Tyr-Boc product was >95% pure and the yield (ε280nm=1130 M−1cm−1) was 95%.
To conjugate Man 9 Tyr-Boc to Cys-(Acr-Lys)4 (SEQ ID NO: 23), the Boc group was removed from the Tyr and the amine terminus was derivatized with propionate maleimide, prior to reaction with Cys-(Acr-Lys)4 (SEQ ID NO: 23). The Boc group was removed by treating Man 9 Tyr-Boc (500 nmol) with 50 μl of 95% TFA for 5 min at RT, followed by freeze drying to remove TFA. The yield of Man 9 Tyr was quantitative and LC-MS analysis established a mass of 2160.3 m/z consistent with the anticipated mass (2160.9 m/z). Man 9 Tyr (500 nmol) was reacted for 1 hr with 3-maleimidoproprionic acid NHS ester (5 μmol) in 250 μl of 50 v/v % DMF and 100 mM sodium bicarbonate. The reaction mixture was fractionated on a Sephadex G-25 column (1.5×50 cm), eluting with 0.1% acetic acid while detecting Abs280 nm The product peak (Man 9 Mal), eluting at 35 ml, was pooled and concentrated by rotary evaporation and purified to homogeneity on a semi-prep Vydac C18 RP-HPLC column (2×25 cm) eluted at 10 ml per min with 0.1% acetic acid and a 30 min acetonitrile gradient (5-15%) resulting in a 23% isolated yield. LC-MS analysis in the negative mode revealed that the Man 9 Mal product produced an ion of 1156.1 m/z, resulting in a mass of 2314.2 m/z, closely corresponding to the anticipated mass of 2312.1.
To complete the glycopeptide synthesis, Man 9 Mal (500 nmol) was reacted with Cys-(Acr-Lys)4 peptide (SEQ ID NO: 23) (600 nmol) in 500 μl of 5 mM Hepes pH 7 for 2 hrs. The Man 9 glycopeptide product was purified from excess dimeric peptide on analytical RP-HPLC with a 30 min 15-30% acetonitrile gradient in 0.1% TFA. The purity and identity of the Man 9 glycopeptide were verified by analytical RP-HPLC detected by Abs280nm and positive mode ESI-MS. The product peak was >95% pure and produced a triply charged ion detected with an m/z of 1390.0 that deconvoluted to an observed mass of 4167.0 m/z (calculated 4167.4 m/z). The recovery was 102 nmol, resulting in a 23% yield.
Man 9 Glycopeptide DNA Band Shift Assay
pGL3 (1 μg) was combined with 0.05, 0.2, 0.5, and 1 nmol of Man 9 glycopeptide. Each sample was incubated for 30 min before loading onto an agarose gel, that was electrophoresed at 80 V for 60 min (Adami, R. C., Collard, W. T., Gupta, S. A., Kwok, K. Y., Bonadio, J., and Rice, K. G. (1998) Stability of Peptide-Condensed Plasmid DNA Formulations. Journal of Pharmaceutical Sciences 87, 678-683). The gel was stained with 0.1 mg per ml of ethidium bromide at 4° C. for 24 hrs, then photographed while illuminating on a transilluminator.
Thiazole Orange Displacement Assay
A control sample of pGL3 (1 μg) was combined with 40 nM thiazole orange in a total volume of 500 μl of 5 mM Hepes buffer pH 7.4. The Man 9 glycopeptide (0.2, 0.3, 0.4, 1 and 2 nmol) or Cys-(Acr-Lys)4 peptide (SEQ ID NO: 23) was added to pGL3 (1 μg) samples containing thiazole orange, and incubated for 30 min, followed by measuring the fluorescence intensity at excitation 500 nm and emission 530 nm (Wadhwa, M. S., Collard, W. T., Adami, R. C., McKenzie, D. L., and Rice, K. G. (1997) Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconjugate Chemistry 8, 81-8). The percent fluorescence intensity relative to control was plotted versus the stoichiometry of glycopeptide or peptide added to DNA to determine the equivalence point.
Glycopeptide DNA Polyplex Binding to DC-SIGN (+) and (−) CHO Cells
pGL3 plasmid (5 μg) was labeled with Label IT according to the manufacturer's instructions to prepare Cy5-DNA. The Man 9 glycopeptide (0.5 nmol) was combined with 1 μg Cy5-DNA in 60 μl of water and incubated for 30 min to form a polyplex. DC-SIGN (+) and (−) CHO cells (1×106) (Granelli-Pipemo, A., Pritsker, A., Pack, M., Shimeliovich, I., Arrighi, J. F., Park, C. G., Trumpfheller, C., Piguet, V., Moran, T. M., and Steinman, R. M. (2005) Dendritic Cell Specific Intercellular Adhesion Molecule 3-Grabbing Nonintegrin/CD209 Is Abundant on Macrophages in the Normal Human Lymph Node and Is Not Required for Dendritic Cell Stimulation of the Mixed Leukocyte Reaction. J Immunology 7, 4260-4273) were each plated in triplicate in 35 mm wells and grown in DMEM supplemented with 7% FBS and 1% nonessential amino acids for 24 hrs. CHO (+) and (−) cells were transfected for 24 hrs with 1 μg of Cy5-DNA polyplex. The CHO cells were lifted by treatment with 5 ml of 1 mM EDTA in PBS and concentrated by centrifugation by 2,000×g, before diluting to a final volume of 1 ml in PBS. The transfected CHO (+) and (−) cells were analyzed by FACS on a Becton Dickson LSRII with excitation 488 nm and emission 575 nm, and compared to untransfected CHO cells.
In Vitro Transfection with Glycopeptide DNA Polyplexes
DC-SIGN (+) CHO cells (1×105) were plated in 6-well plates in triplicate in 1 ml DMEM high glucose supplemented with 7% FBS and 1% MEM non-essential amino acids. After incubation for 24 hrs at 37° C. in 5% CO2, the media was removed, the cells were washed with 1 ml DPBS, replaced with 1 ml DMEM high glucose media supplemented with 2% FBS and 0.3% MEM non-essential amino acids.
Cells were transfected in triplicate for 24 hrs with pGL3 polyplexes (1 μg DNA and 0.6 nmol of glycopeptide in a total volume of 30 μl). The efficiency of glycopeptide DNA polyplex transfection was compared with PEI-DNA transfection performed by combining 1 μg DNA with 1.2 μg of PEI (N:P of 9) in 100 μl of 5 mM Hepes, 270 mM mannitol, pH 7.4. After 24 hrs, cells were washed with 2 ml of DPBS and lysed with 0.5 ml of lysis buffer (25 mM tris chloride, 1 mM EDTA, 8 mM magnesium chloride, 1% Triton X-100, pH 7.8) for 10 min at 4° C. Cell lysates were scraped, transferred to 1.5 ml microcentrifuge tubes, and centrifuged for 10 mM at 13,000 g (at 4° C.) to pellet cell debris. Lysis buffer (400 μl) and ATP (4.3 μl of a 165 mM solution at pH 7) were combined in a test tube, mixed briefly, and placed in the luminometer. The relative light units were determined with 10 sec integration after automatic injection of 100 μl of 0.43 mM D-luciferin. Protein concentrations were measured by a BCA assay with bovine serum albumin as a standard (Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150, 76-85). The amount of luciferase recovered in each sample was normalized to mg of protein and reported as the mean with standard deviation obtained from triplicate transfections.
Results
A strategy was developed to reversibly bind a high mannose N-glycan to plasmid DNA for the purpose of targeted uptake and expression of a reporter gene in cells expressing the DC-SIGN receptor. While in the present study, glycopeptide mediated gene transfer was only tested in a model cell system, the ultimate purpose of this gene delivery system would be to selectively transfect dendritic cells in humans to improve the efficacy of DNA vaccines.
The polyacridine peptide was designed to reversibly bind to plasmid DNA by a combination of intercalation. The solid phase synthesis of Cys-(Acr-Lys)4 (SEQ ID NO: 23) necessitated the large scale synthesis of Fmoc-Lys(Acr) as an unnatural amino acid. Using this approach, a high affinity polyacridine peptide containing an N-terminal Cys was obtained in good yield.
The high-mannose N-glycan is a known ligand for DC-SIGN receptor and is the only N-glycan present on SBA. Because SBA is a galactose specific lectin, it is readily purified in a single affinity chromatography step. The affinity purification of SBA is essentially the same as first reported by (Sharon L is, H., Sharon, N., and Katchalski, E. (1966) Soybean Hemagglutinin, a Plant Glycoprotein. I. Isolation of a Glycopeptide. J. Biol. Chem. 241, 684-689), with the exception that the affinity resin was prepared by attaching galactosamine to 6-aminohexanoic acid functionalized Sepharose resin prepared using CDI as reported by Bethel and Ayers (Bethell, G. S., Ayers, J. S., Hancock, W. S., and Hearn, M. T. (1979) A novel method of activation of cross-linked agarose with 1,1′-carbonyldiimidazole which gives a matrix for affinity chromatography devoid of additional charged groups. J Biol Chem 254, 2572-4). This approach afforded the scalable preparation of the column resin without the use of cyanogen bromide.
The high-mannose N-glycan on SBA is not easily released by direct treatment with N-glycosidase F. Likewise, affinity purified SBA is very resistant to digestion with trypsin. Consequently, SBA is most efficiently converted to peptides by prolonged pronase digestion which produces the Man 9 N-glycan possessing a single Asn. Starting with 10 g of soy flour, the resulting Man 9 N-glycan was purified in good yield (6.7 μmols, 45%) using a combination of gel filtration and cation exchange chromatography as described (L is, H., Sharon, N., and Katchalski, E. (1966) Soybean Hemagglutinin, a Plant Glycoprotein. I. Isolation of a Glycopeptide. J. Biol. Chem. 241, 684-689; Gordon, J. A., Blumberg, S., Lis, H., and Sharon, N. (1972) Purification of Soybean Agglutinin by Affinity Chromatography of Sepharose-N-e-Aminocaproyl-B-D-Galactopyranosylamine. Febs Letters 24, 193-196). High field 1H-NMR analysis of the purified Man 9 N-glycan established the presence of 9 mannose residues based on the resonance frequency of the anomeric proton for each. MALDI-TOF analysis was also consistent with the isolation of Man 9 N-glycan containing a single Asn residue.
The conjugation of the Man 9 N-glycan to Cys-(Acr-Lys)4 (SEQ ID NO: 23) required functionalization through the Asn residue (
To complete the synthesis of the Man 9 glycopeptide, the Man 9 Mal was reacted with nearly a stoichiometric amount of Cys-(Acr-Lys)4 (SEQ ID NO: 23) (
To examine the binding of the Man 9 glycopeptide to DNA, an agarose gel electrophoresis band shift assay was used. The electrophoretic migration of DNA was significantly retarded at increasing glycopeptide to DNA stoichiometry such that at 0.4 nmol of glycopeptide per μg of DNA or higher the band shift was complete (
An additional analysis of glycopeptide DNA binding affinity utilized a fluorophore displacement assay. Increasing the stoichiometry of Man 9 glycopeptide to DNA resulted in the displacement of thiazole orange from DNA as determined by a decrease in fluorescence intensity. An asymptote in the fluorescence intensity at 0.4 nmol Man 9 glycopeptide per 1 μg DNA established this as the equivalence point for polyplex formation (
The uptake of Man 9 glycopeptide Cy5-DNA polyplexes into CHO cells, either with (+) or without (−) stably transfected DC-SIGN receptor, was assayed by FACS analysis (
To determine if the increased uptake of Man 9 glycopeptide DNA polyplexes by CHO (+) cells results in increased gene expression, a series of gene transfer experiments were performed in CHO (+) and (−) cells. The results established that PEI-DNA polyplexes were the most efficient in gene transfer but were not selective for (+) or (−) cells (
Discussion
The clinical application of DNA vaccines for the treatment of disease is currently limited by the low efficiency of nonviral delivery systems. While it will be possible to optimize the DNA vector, it is also necessary to improve the delivery system. A large body of growing evidence suggests that targeting of DNA, as well as adjuvant, to enter dendritic cells leads to an enhanced immune response. It has been demonstrated that DC-SIGN is an endocytosing, cell surface C-type lectin that can be used to target proteins and DNA into dendritic cells. Given that the specificity of DC-SIGN is for mannose or LeX on N-glycans, we explored an approach to reversibly attach a high-mannose N-glycan ligand to plasmid DNA to establish DNA uptake and gene expression in cells expressing DC-SIGN.
To achieve this, a purification of a high-mannose N-glycan from soybean agglutinin was used. This required the development of a large-scale galactose affinity column by applying a carbodiimide coupling strategy. The purified N-glycan was then systematically modified on the Asn N-terminus to allow coupling to a DNA binding peptide. The conjugation of Boc-Tyr resulted in introduction of a hydrophobic chromophore that could be iodinated. Removal of Boc proceeded in neat TFA to afford the Tyr amine. Modification of the amine with a propionate possessing a maleimide group resulted in a Man 9 Mal that reacted with a thiol on the peptide.
The polyacridine peptide was modeled after similar peptides first reported by Ueyama (Ueyama, H., Takagi, M., Waki, M., and Takenaka, S. (2001) DNA binding behavior of peptides carrying acridinyl units: First example of effective poly-intercalation. NUCLEIC ACIDS SYMP SER (OXF) 1, 163-164). However, a Cys residue was included on the N-terminus to allow specific coupling to Man 9 Mal. This conjugation led to a Man 9 glycopeptide that possessed affinity for DC-SIGN and DNA. The DNA binding affinity of a polyacridine peptide is related to the number of acridines and the identity of the spacing amino acid. Two different experiments established that the glycopeptide binds to DNA. A band shift assay and a fluorophore displacement assay both confirmed that the Man 9 glycopeptide binds maximally to DNA at 0.4 nmol per μg of DNA. The binding affinity for the unglycosylated peptide was slightly greater than that of the glycopeptide.
The ability of DC-SIGN to bind to Man 9 glycopeptide DNA polyplexes was established using a CHO cell line stably transfected with the human DC-SIGN receptor. The results of FACS analysis using Cy5-DNA glycopeptide polyplexes confirmed preferential binding to CHO (+) cells compared to CHO (−) cells. It should be noted that Cy5-DNA glycopeptide polyplexes bind weakly to CHO (−) cells perhaps due to the cationic nature of the polyplexes.
The results of FACs analysis compare favorably with those of gene transfer studies. A 100-fold increase in gene transfer was determined when transfecting CHO (+) cells with glycopeptide DNA polyplexes compared to the same transfection of CHO (−) cells. Unglycosylated peptide formed cationic polyplexes that mediated non-specific gene transfer. While the levels of gene transfer are much lower than that mediated by PEI DNA, the selectivity of Man 9 glycopeptide mediated gene transfer support the hypothesis that DC-SIGN binds the ligand and transports the DNA polyplex into the cell.
Taken together, this study demonstrates the first application of a high-mannose N-glycan to mediated gene transfer via DC-SIGN, and demonstrates the application of a polyacridine anchor peptide to reversibly bind Man 9 to DNA. These results may be expanded to eventually improve the efficacy of DNA vaccines for use in humans.
A new class of gene delivery peptides were developed and tested in mice. The peptides of the general structure (Acr-X)n, possessed from 2-6 repeats of a modified Lys, with acridine (Acr) attached to the c-amine of Lys, spaced by amino acid X (SEQ ID NO: 89). (Fernandez, C. A. Baumhover, N. J., Duskey, J., Khangharia, S., Kizzire, K., Ericson, M., and Rice, K. G. “Metabolically Stabilized Long-Circulating PEGylated Polyacridine Peptide Polyplexes Mediate Hydrodynamically Stimulated Gene Expression in Liver” Gene Therapy (2011) 18, 23-37.) The number of Acr repeats and the identity of the spacing amino acid were studied in relation to the DNA binding affinity, metabolic stability, pharmacokinetic half-life and in vivo gene transfer efficiency. Each peptide possessed a C-terminal Cys that was modified either reversibly or irreversibly with polyethylene glycol (PEG5000 Da). PEGylated polyacridine peptides were examined for DNA binding affinity by dye displacement and gel band shift, for particle size and zeta potential using QELS, and for shape using atomic force microscopy (AFM). Substitution of (Acr-X)4-Cys-PEG, with X as either Lys, Arg, Leu or Glu (SEQ ID NO: 90), established that polyacridine peptides possessing a Lys and Arg bind with higher affinity than peptides possessing Leu and Glu. Increasing the number of Acr-Lys repeats from 2 to 6 resulted in increased DNA binding affinity and greater protection of DNA from DNase. Pharmacokinetic analysis of PEGylated (Acr-Lys)6 polyplexes (SEQ ID NO: 33) established the metabolic stability of plasmid DNA with a long-circulatory half-life of 3 hrs in blood. A high level of luciferase expression was stimulated in the liver following a tail vein dose of PEGylated polyacridine peptide pGL3 polyplexes (1 μg in 50 μl). Administration of the stimulatory hydrodynamic dose of normal saline at times ranging from 5-60 min post-DNA administration, resulted in liver expression that was equal or greater than the level mediated by direct hydrodynamic dosing of pGL3 (1 μg). The results establish the unique properties of PEGylated polyacridine peptides that facilitate reversible binding to plasmid DNA, protect it from DNase in vivo, allow it to circulate for hours, and release transfection-competent DNA into the liver to mediate high-level gene expression.
Introduction
New gene delivery agents are needed that function by efficiently mediating targeted nonviral gene delivery in vivo. Some of the most successful delivery agents developed to date, such as PEI and cationic lipids, produce robust gene transfer in vitro, but fail to mediate significant gene expression in vivo. In contrast, hydrodynamic (HD) dosing and electroporation are proven physical methods that are highly efficient in delivering plasmid DNA to animals and may find utility in humans. However, due to the invasiveness of HD dosing, there is a need for new gene delivery agents that produce gene expression at levels comparable to HD dosing, but without the requirement of high-volume administration.
Most i.v. dosed nonviral gene delivery systems are cationic polyplexes or lipoplexes, the primary exception being anionic liposomes with encapsulated DNA. To increase their compatibility with blood, cationic polyplexes are modified with polyethylene glycol (PEG) to block albumin binding and to “stealth” their rapid endocytosis by cells of the reticuloendothelial system (RES). Despite these attempts, most PEGylated cationic polyplexes still quickly biodistribute to the liver, and are taken-up primarily by Kupffer cells. Few, if any, of these experimental i.v. dosed gene delivery systems have produced appreciable gene expression in the liver, especially when compared to the level of luciferase expression from an equivalent dose of DNA delivered hydrodynamically.
To develop nonviral gene delivery agents that function with greater efficiency in vivo following i.v. dosing, it is necessary to control the size, charge and metabolic stability of polyplexes. The cationic surface charge of most polyplexes results from residual unpaired amines on the cationic polymer used to condense DNA. Anionic polyplexes may be more blood compatible, but would require a new mode of binding polymers to DNA, not based on electrostatic interaction.
The use of polyintercalation has been shown to increase the binding affinity of small polymers and peptides to DNA. Previous studies from our group have established that polyacridine peptides possessing four Lys(Acr) residues (ε amine of Lys is modified with acridine), spaced by either a Lys or Arg, produce high affinity binding for plasmid DNA. Modification of polyacridine peptides with either a fusogenic peptide (melittin) or an N-glycan (high-mannose) produced gene transfer agents that formed cationic polyplexes resulting in high level selective gene transfer in vitro. PEGylated polyacridine peptides have been shown to bind to plasmid DNA and produce unique, metabolically stable, anionic open-polyplexes that are capable of mediating gene transfer in vivo when delivered by i.m.-electroporation.
In the present study we prepared a panel of PEGylated polyacridine peptides to establish their utility in mediating gene expression following i.v. dosing. The results establish a clear structure-activity relationship by which protection of the DNA in blood and liver by a PEGylated polyacridine peptide results in the ability to stimulate high level gene expression in liver with a delayed hydrodynamic dose of saline. The results also establish the ability to extend the circulatory half-life of a significant percentage of i.v. dosed DNA, which is an important prerequisite of achieving targeted gene delivery to organs and tissues. The synthetic adaptability of polyacridine peptides, along with the ability to prepare either anionic-open or cationic-closed-polyplexes that mediate gene transfer in vivo, demonstrate the unique importance of poly-intercalative binding to achieve gene delivery.
Materials and Methods
Unsubstituted Wang resin, 9-hydroxybenzotriazole, Fmoc-protected amino acids, O-(7-Azabenzo-triazol-1-yl)-N,N,N′,N′-tetramethylurionium hexafluorophosphate (HATU), Fmoc-Lysine-OH, and N-Methyl-2-pyrrolidinone (NMP) were obtained from Advanced ChemTech (Lexington, Ky.). N,N-Dimethylformamide (DMF), trifluoroacetic acid (TFA), and acetonitrile were purchased from Fisher Scientific (Pittsburgh, Pa.). Diisopropylethylamine, piperidine, acetic anhydride, Tris(2-carboxyethyl)-phosphine hydrochloride (TCEP), 9-chloroacridine and thiazole orange were obtained from Sigma Chemical Co. (St. Louis, Mo.). Agarose was obtained from Gibco-BRL. mPEG-maleimide and mPEG-OPSS (5,000 Da) were purchased from Laysen Bio (Avab, Ala.). D-Luciferin and luciferase from Photinus pyralis were obtained from Roche Applied Science (Indianapolis, Ind.). pGL3 control vector, a 5.3 kb luciferase plasmid containing a SV40 promoter and enhancer, was obtained from Promega (Madison, Wis.). pGL3 was amplified in a DH5α strain of Escherichia coli and purified according to manufacturer's instructions.
Synthesis and Characterization of Polyacridine Peptides
9-Phenoxyacridine and Fmoc-Lysine(Acridine)-OH were prepared as recently reported (Baumhover N J, Anderson K, Fernandez C A, Rice K G. Synthesis and In Vitro Testing of New Potent Polyacridine-Melittin Gene Delivery Peptides, Bioconjugate Chemistry 2010; 21: 74-86; Anderson, K, Fernandez, C. A., and Rice, K. G. “N-Glycan Targeted Gene Delivery to the Dendritic Cell SIGN Receptor” Bioconjugate Chemistry (2010) 21, 1479-85). The polyacridine peptides reported in Table 1 were prepared by solid phase peptide synthesis on a 30 μmol scale on an APEX 396 Synthesizer using standard Fmoc procedures including 9-hydroxybenzotriazole and HATU activation while employing double coupling of Fmoc-Lys(Acr)-OH and triple coupling for the spacing amino acid while using a 5-fold excess of amino acid over resin and omitting N-capping of truncated peptide species.
aDetermined by ESI-MS.
bDetermined by MALDI-TOF MS.
Peptides were removed from resin and side chain deprotected using a cleavage cocktail of TFA/ethanedithiol/water (93:4:3 v/v/v) for 3 hrs followed by precipitation in cold ether. Precipitates were centrifuged for 10 min at 5000×g at 4° C. and the supernatant decanted. Peptides were then reconstituted with 0.1 v/v % TFA and purified to homogeneity on RP-HPLC by injecting 0.5-2 μmol onto a Vydac C18 semi-preparative column (2×25 cm) eluted at 5 ml per min with 0.1 v/v % TFA with an acetonitrile gradient of 20-30 v/v % over 30 min while monitoring acridine at 409 nm. The major peak was collected and pooled from multiple runs, concentrated by rotary evaporation, lyophilized, and stored at −20° C. Purified peptides were reconstituted in 0.1 v/v % TFA and quantified by absorbance (acridine ε409 nm=9266 M−1 cm−1 assuming additivity of c for multiple acridines) to determine isolated yield (Table 4). Purified peptides were characterized by LC-MS by injecting 2 nmol onto a Vydac C18 analytical column (0.47×25 cm) eluted at 0.7 ml per min with 0.1 v/v % TFA and an acetonitrile gradient of 10-55 v/v % over 30 min while acquiring ESI-MS in the positive mode.
Synthesis and Characterization of PEGylated Polyacridine Peptides
PEGylation of the Cys residue on (Acr-X)n-Cys was achieved by reacting with 1 mol of peptide with 1.1 mol of PEG5000 Da-maleimide or PEG5000 Da-OPSS in 4 ml of 10 mM ammonium acetate buffer pH 7 for 12 hrs at RT. PEGylated peptides were purified by semipreparative HPLC as previously described and eluted with 0.1 v/v % TFA with an acetonitrile gradient of 25-65 v/v % acetonitrile while monitoring acridine at 409 nm. The major peak was collected and pooled from multiple runs, concentrated by rotary evaporation, lyophilized, and stored at −20° C. Counter-ion exchange was accomplished by chromatography on a G-25 column (2.5×50 cm) equilibrated with 0.1 v/v % acetic acid to obtain the peptide in an acetate salt form. The major peak corresponding to the PEG-peptide eluted in the void volume (100 ml) was pooled, concentrated by rotary evaporation, and freeze-dried. PEG-peptides were reconstituted in water and quantified by Abs409nm to determine isolated yield (Table 4). PEG-peptides were characterized by MALDI-TOF MS by combining 1 nmol with 10 μl of 2 mg per ml a-cyano-4-hydroxycinnamic acid (CHCA) in 50 v/v % acetonitrile and 0.1 v/v % TFA. Samples were spotted onto the target and ionized on a Bruker Biflex III Mass Spectrometer operated in the positive ion mode.
Formulation and Characterization of PEGylated Polyacridine Peptide Polyplexes
The relative binding affinity of PEGylated polyacridine peptides for DNA was determined by a fluorophore exclusion assay (Wadhwa M S et al. Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconjugate Chemistry 1997; 8: 81-88). pGL3 (200 μl of 5 μg/ml in 5 mM Hepes pH 7.5 containing 0.1 μM thiazole orange) was combined with 0, 0.05, 0.1, 0.25, 0.35, 0.5, or 1 nmol of PEGylated polyacridine peptide in 300 of Hepes and allowed to bind at RT for 30 min. Thiazole orange fluorescence was measured using an LS50B fluorometer (Perkin-Elmer, U.K.) by exciting at 498 nm while monitoring emission at 546 nm with the slit widths set at 10 nm. A fluorescence blank of thiazole orange in the absence of DNA was subtracted from all values before data analysis. The data is presented as nmol of PEGylated polyacridine peptide per μg of DNA versus the percent fluorescence intensity±the standard deviation determined by three independent measurements.
The particle size and zeta potential were determined by preparing 2 ml of polyplex in 5 mM Hepes pH 7.5 at a DNA concentration of 30 μg per ml and a PEGylated polyacridine peptide stoichiometry of 0, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8 or 1 nmol per μg of DNA. The particle size was measured by quasi-elastic light scattering (QELS) at a scatter angle of 90° on a Brookhaven ZetaPlus particle sizer (Brookhaven Instruments Corporation, NY). The zeta potential was determined as the mean of ten measurements immediately following acquisition of the particle size.
The shape of PEGylated polyacridine polyplexes were determined using atomic force microscopy (AFM). pGL3 alone, or anionic PEGylated polyacridine polyplexes at 0.2 nmol of peptide per μg of DNA, were prepared at a concentration of 100 μg per ml of DNA in 10 mM Tris, 1 mM EDTA pH 8. Polyplexes were diluted to 1 μg per ml in 40 mM Hepes 5 mM nickel chloride pH 6.7 and deposited on a fresh cleaved mica surface (cationic mica) for 10 min followed by washing with deionized water. Cationic PEGylated polyacridine polyplexes prepared at 0.8 nmol of PEGylated (Acr-Lys)6 (SEQ ID NO: 33) per μg of DNA, at 100 μg per ml of DNA in 10 mM Tris, 1 mM EDTA pH 8 were deposited directly on a freshly cleaved mica surface (anionic mica) and allowed to bind for 10 min prior to washing with deionized water. Images were captured using an Asylum AFM MFP3D (Santa Barbara, Calif.) operated in the AC-mode using a silicon cantilever (Ultrasharp NSC15/AIBS, Mikro Masch).
Gel Band Shift and DNase Protection Assay
pGL3 (1 μg), or pGL3 polyplexes (1 μg) were prepared at either 0.2 or 0.8 nmol of PEGylated (Acr-Lys)2, 4, or 6 (SEQ ID NOS 32, 29, and 33, respectively), in 20 μl of 5 mM Hepes buffer pH 7.4. The ability of polyplexes to resist digestion with DNase was determined by incubation with 0.06 U of DNase I for 10 min. DNase was inactivated by the addition of 500 μl of 0.5 mg per ml proteinase K (in 100 mM sodium chloride, 1% SDS and 50 mM Tris pH 8.0) followed by incubation at 37° C. for 30 min. The polyplexes were extracted with 500 μl of phenol/chloroform/isoamyl alcohol (24:25:1) to remove PEGylated peptides, followed by precipitation of DNA with the addition of 1 ml of ethanol. The precipitate was collected by centrifugation at 13,000 g for 10 min, and the DNA pellet was dried and dissolved in 5 mM Hepes buffer pH 7.4. DNA samples were combined with 2 μl of loading buffer and applied to a 1% agarose gel (50 ml) and electrophoresed in TBE buffer at 70 V for 60 min (Adami R C, Rice K G. Metabolic stability of glutaraldehyde cross-linked peptide DNA condensates. Journal of Pharmaceutical Sciences 1999; 88: 739-746). The gel was post-stained with 0.1 μg per ml ethidium bromide at 4° C. overnight then imaged on a UVP Biospectrum Imaging System (Upland, Calif.).
Pharmacokinetic Analysis of PEGylated Polyacridine Polyplexes.
Radioiodinated pGL3 was prepared as previously described (Terebesi J, Kwok K Y, Rice K G. Iodinated plasmid DNA as a tool for studying gene delivery. Analytical Biochemistry 1998; 263: 120-123). Triplicate mice were anesthetized by i.p. injection of ketamine hydrochloride (100 mg per kg) and xylazine hydrochloride (10 mg per kg) then underwent a dual cannulation of the right and left jugular veins. An i.v. dose of 125I-DNA (3 μg in 50 μl of HBM, 1.2 μCi) or 125I-DNA polyplex (3 μg) was administered via the left catheter, and blood samples (10 μl) were drawn from the right catheter at 1, 3, 6, 10, 20, 30, 60, 90 and 120 min and immediately frozen, then replaced with 10 μl of normal saline. The amount of radioactivity in each blood time point was quantified by direct γ-counting followed by extraction of the DNA and separation by gel electrophoresis as described above. The gel was dried on a zeta probe membrane and autoradiographed on a Phosphor Imager (Molecular Devices, Sunnyvale Calif.) following a 15 hr exposure.
Biodistribution Analysis of PEGylated Polyacridine Polyplexes
Triplicate mice were anesthetized and a single catheter was placed in the left jugular vein. 125I-DNA (1.5 μg in 50 μL of HBM, 0.6 μCi) or 125I-DNA polyplexes (1.5 μg) were dosed i.v. followed by vein ligation. After 5, 15, 30, 60, or 120 min, mice were sacrificed by cervical dislocation and the major organs (liver, lung, spleen, stomach, kidney, heart, large intestine, and small intestine) were harvested, and rinsed with saline. The radioactivity in each organ was determined by direct γ-counting and expressed as the percent of the dose in the organ.
Hydrodynamic Stimulation and Bioluminescence Imaging
pGL3 (1 μg) was prepared in a volume of normal saline corresponding to 9 wt/vol % of the mouse's body weight (1.8-2.25 ml based on 20-25 g mice). The DNA dose was administered by tail vein to 4-5 mice in 5 sec according to a published procedure (Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266; Zhang G, Budker V, Wolff J A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Human Gene Therapy 1999; 10: 1735-1737). Mice (4-5) were also dosed tail vein with 1 μg of PEGylated polyacridine polyplex in 50 μl of HBM (5 mM Hepes, 0.27 M mannitol, pH 7.4). At times ranging from 5-120 min, a stimulatory hydrodynamic dose of normal saline (9 wt/vol % of the body weight) was administered over 5 sec. At 24 hrs post-DNA dose, mice were anesthetized by 3% isofluorane, then administered an i.p. dose of 80 μl (2.4 mg) of D-luciferin (30 μg/μl in phosphate-buffered saline). At 5 min following the D-luciferin dose, mice were imaged for bioluminescence (BLI) on an IVIS Imaging 200 Series (Xenogen). BLI was performed in a light-tight chamber on a temperature-controlled, adjustable stage while isofluorane was administered by a gas manifold at a flow rate of 3%. Images were acquired at a ‘medium’ binning level and a 20 cm field of view. Acquisition times were varied (1 sec−1 min) depending on the intensity of the luminescence. The Xenogen system reported bioluminescence as photons/sec/cm2/seradian in a 2.86 cm diameter region of interest covering the liver. The integration area was transformed to pmols of luciferase in the liver using a previously reported standard curve (Rettig G et al. Quantitative Bioluminscence Imaging of Transgene Expression In Vivo. Analytical Biochemistry 2006; 335: 90-94). The results were determined to be statistically significant (p≦0.05) based on a two-tailed unpaired t-test.
Results
A panel of PEGylated polyacridine peptides were prepared and tested for their ability to bind and transport DNA in vivo. The peptides were designed to test the influence of DNA binding affinity on gene transfer efficiency. To examine the influence of spacing amino acid, four peptides of the general structure (Acr-X)4 were prepared, where X is either Lys, Arg, Leu or Glu (SEQ ID NO: 99) (Table 4). As discussed in more detail below, a Lys spacing amino acid proved most efficient in gene transfer, which warranted an expansion of (Acr-Lys)n to include repeats of 2 and 6 (SEQ ID NO: 100) (Table 4). Each polyacridine peptide also possessed a C-terminal Cys residue to allowed modification with PEG. During the course of synthesis, the synthetic yields of polyacridine peptides were improved by using HATU to activate amino acids during coupling. Improved yields were also the result of applying triple coupling of the spacing amino acids, omitting N-capping to avoid a side reaction with acridine, and using ethanedithiol as a scavenger during workup. Under these conditions, (Acr-Lys)n with repeats ranging from 2 to 6 (SEQ ID NO: 101) were prepared in 20-37% isolated yield (Table 1). Each polyacridine peptide produced an ESI-MS consistent with the calculated mass (Table 4).
Conjugation of each polyacridine peptide with PEG was accomplished by reaction of the Cys residues with either PEG-maleimide or PEG-OPSS, resulting in PEGylated polyacridine peptides with a reducible disulfide or a non-reducible maleimide linkage (
The relative binding affinity of PEGylated polyacridine peptides for pGL3 was compared by determining the concentration of peptide that displaces a thiazole orange intercalator dye, resulting in decreased fluorescence.
Comparison of PEGylated (Acr-X)4 (X is either Arg, Lys, Leu or Glu (SEQ ID NOS 28-31, respectively)) established the importance of cationic amino acids to increase binding affinity. Both the Lys and Arg analogue demonstrated high affinity by completely displacing thiazole orange at 0.4 nmol of peptide per μg of DNA. Conversely, the Leu analogue demonstrated weaker binding, resulting in full displacement at 1 nmol, and the Glu analogue was determined to have the lowest affinity by only achieving 40% displacement at 1 nmol (
A similar comparison of the binding affinities for PEGylated (Acr-Lys)2, 4 and 6 (SEQ ID NOS 32, 29, and 33, respectively)established a relationship of increasing affinity with increasing the number of Acr, such that PEGylated (Acr-Lys)6 (SEQ ID NO: 33)completely displaced thiazole orange at 0.2 nmols of peptide per μg of DNA (
The size and charge of DNA polyplexes are often a function of the stoichiometry of peptide bound to DNA. To examine this relationship for PEGylated polyacridine polyplexes, QELS particle size and zeta potential were measured as a function of peptide to DNA ratio. One unusual property of PEGylated polyacridine polyplexes was their QELS mean diameter remained constant throughout the titration (
A second unusual property of PEGylated polyacridine polyplexes was the observed zeta potential at each peptide stoichiometry (
The shape and relative charge of PEGylated polyacridine polyplexes was further examined by atomic force microscopy (AFM) (
The unique shape and charge of anionic PEGylated open-polyplexes should minimize binding to serum proteins and extend the pharmacokinetic half-life of plasmid DNA, provided that the DNA remains protected from premature metabolism. To investigate the metabolic stability of DNA polyplexes, PEGylated (Acr-Lys)2, 4, and 6 polyplexes (SEQ ID NOS 32, 29, and 33, respectively) were digested with DNase, followed by phenol-chloroform extraction to remove peptide and gel electrophoresis to determine the status of the plasmid DNA (
PEGylated polyacridine peptides were also subjected to trypsin digestion to determine if they could be digested by a common serine protease, suggesting perhaps they could also be more easily cleared from cells. The results established that even as little as 100 mU of trypsin catalyzed the formation of a dipeptide of Lys-Lys(Acr) with mass of 451 g/mol, to a reaction completion within 1 hr. Thereby, the high-affinity DNA binding of PEGylated polyacridine peptides is greatly reduced upon proteolytic digestion.
To determine if polyacridine peptides would mediate gene transfer, we chose to examine the ability of PEGylated DNA polyplexes to produce luciferase expression in the liver of mice, 24 hrs following a 1 μg dose of pGL3. Hydrodynamic dosing of 1 μg of pGL3 produced 108 photon/sec/cm2/sr determined using a calibrated bioluminescence assay (
At a fixed dose of 1 μg of pGL3 and a time delay of 30 min between primary and stimulatory dose, polyplexes prepared at 0.5 nmol of PEGylated (Acr-Arg)4 (SEQ ID NO: 28), in which the PEG was attached by a maleimide (Mal) or a reducible disulfide (SS) linkage, were administered to mice and analyzed by BLI after 24 hrs. Approximately 5-fold higher luciferase expression was observed for Mal versus SS, indicating that a reducible linkage offered no advantage for stimulated expression (
Several controls were applied to further establish that PEGylated polyacridine peptides were necessary to achieve stimulated expression. The administration of a 1 μg dose of pGL3 followed by a stimulatory dose of saline after 30 min resulted in no detectable luciferase expression at 24 hrs (
The stimulated expression mediated by PEGylated (Acr-Arg)4 polyplexes (SEQ ID NO: 28) (1 μg) was examined to determine the influence of the delay time between primary and stimulatory dose. Varying the delay from 5-120 min established a 10-fold loss in luciferase expression between 5 and 30 min, followed by a complete loss of stimulated expression at 60 min and longer (
To determine how the spacing amino acid influence stimulated gene expression, PEGylated peptides of general structure (Acr-X)4, possessing X as either Lys, Arg, Leu or Glu (SEQ ID NOS 29, 28, 30, and 31, respectively) were used to prepare polyplexes that were dosed in mice and stimulated to express luciferase. While the DNA dose was fixed at 1 μg, and the time delay was 30 min, the stoichiometry of PEGylated peptide to DNA was adjusted based on the results of zeta potential titration (
The stoichiometry of both Lys and Arg spaced PEGylated polyacridine peptide were varied from 0.2-1 nmol of peptide per μg of DNA, then dosed via tail vein and stimulated after 30 min. A 1 μg open polyplex prepared with 0.6 nmol of PEGylated (Acr-Arg)4 (SEQ ID NO: 28) or 0.8 nmol of PEGylated (Acr-Lys)4 (SEQ ID NO: 29) mediated maximal luciferase expression when assayed by BLI at 24 hrs (
Comparison of the stimulated gene expression (30 min) mediated by
PEGylated (Acr-Lys)2, 4 and 6 polyplexes (SEQ ID NOS 32, 29, and 33, respectively) (1 μg pGL3) prepared at an optimized stoichiometry of 1, 0.8 and 0.2 nmols of peptide respectfully (based on zeta potential,
When PEGylated (Acr-Lys)6 polyplexes (SEQ ID NO: 33) were administered to mice to determine how changing stoichiometry influenced gene expression, the results established that a 1 μg dose of pGL3 polyplex, stimulated at 30 min, produced equivalent gene expression across the range of 0.2-0.8 nmols of peptide (
To determine if the unique DNA binding properties of PEGylated (Acr-Lys)6 (SEQ ID NO: 33) would also extend the delay time allowed between primary and stimulatory dose, polyplexes (1 μg) were prepared with 0.2 nmols of peptide and administered with a time delay varying from 0 to 120 min. Delaying the stimulation from 5 to 60 min resulted in only a slight 2-3 fold decrease in expression, whereas with a 120 min delay the expression decreased 100-fold (
To establish the dose-equivalency of direct HD administration of DNA, relative to the stimulated expression of PEGylated polyacridine polyplexes, a dose-response experiment was performed (
To gain further mechanistic insight into the reason that PEGylated polyacridine polyplexes mediate stimulated gene expression, pharmacokinetic and biodistribution studies were performed. Following i.v. dosing of 125I-DNA or PEGylated (Acr-Lys)2 polyplexes (SEQ ID NO: 32) resulted in a rapid 10-fold loss of radioactivity from the blood within 20-30 min, followed by an apparent long half-life (
The pharmacokinetic profile for PEGylated (Acr-Lys)4 and 6 125I-DNA polyplexes (SEQ ID NOS 29 and 33, respectively) were both very similar and distinct from those of 125I-DNA and PEGylated (Acr-Lys)2 125I-DNA polyplexes (SEQ ID NO: 32) (
125I-DNAg (SEQ ID
125I-DNAh (SEQ ID
125I-DNAi (SEQ ID
aCalculated α-half-life.
bCalculated β-half-life.
cVolume of distribution.
dTotal body clearance rate.
eMean residence time.
fArea under the curve.
gCalculated using blood cpm values over 20 min, assuming complete DNA stability.
hCalculated using blood cpm values over 60 min, assuming complete DNA stability.
iCalculated using blood cpm values over 120 min, assuming complete DNA stability.
For the purpose of comparison, complete metabolic stability of plasmid DNA was assumed in the pharmacokinetic calculation, even though the gel electrophoretic and autoradiographic analysis for PEGylated (Acr-Lys)2 and (Acr-Lys)4 (SEQ ID NOS 32 and 29, respectively) establish the differential loss of intact DNA over time. The apparent clearance rate decrease and the mean residence time increased as the β-half-live increased, whereas the apparent volume of distribution remained nearly constant. This resulted in an increase in the AUC as the stability of the polyplex increased (Table 5).
The unique long pharmacokinetic β-half-life for PEGylated (Acr-Lys)4 and 6 polyplexes (SEQ ID NOS 29 and 33, respectively) and the nearly coincident volume of distribution suggested there would be similar biodistribution to the organs. The experimental result established that the liver was the major site of biodistribution for PEGylated (Acr-Lys)2, 4 and 6 125I-DNA polyplexes (SEQ ID NOS 32, 29, and 33, respectively) (Table 6). In each of these experiments, it was not possible to extract 125I-DNA from liver or other tissues to determine its metabolic status, as was performed for DNA in blood.
125I-DNA
125I-DNA
125I-DNA
125I-DNA
aPercent of dose based on pharmacokinetic analysis.
bPercent of dose based on gamma counting of tissue.
cTotal percent of dose recovered.
The biodistribution of 125I-DNA and PEGylated (Acr-Lys)2 125I-DNA polyplexes (SEQ ID NO: 32) both reached a maximum of approximately 65% in the liver at 5 min, followed by a decrease to less than 10% by 120 min (
Discussion
PEGylated polyacridine peptides were designed to bind to plasmid DNA for the purpose of making it more blood compatible as a first step toward ultimately adding a targeting ligand and sub-cellular targeting peptides, needed to complete the delivery system and achieve significant in vivo gene expression following i.v. dosing, without the requirement of an additional stimulation. To accomplish this goal, an optimal polyacridine peptide would need to bind to DNA with sufficient affinity to protect from DNase metabolism in the circulation, while being able to release the DNA inside the cell to gain access to the nucleus.
It is likely there are many unique sequences of polyacridine peptides that accomplish this goal. The aim of the structure-activity study described was to determine a relationship between the number of Acr, the binding affinity for DNA, the polyplex pharmacokinetic half-life, and the magnitude of stimulated expression in mice. Initially, a nine amino acid peptide allowed the incorporation of four Acr spaced by a hydrophobic (Leu), anionic (Glu), or cationic (Lys and Arg) residue, along with a C-terminal Cys for modification. Prior studies from our group established that spacing amino acids that lacked a bulky side-chain or protecting group (Gly or Ala) resulted in low peptide yields. During the course of this study it was necessary to further optimize peptide yield to prepare (Acr-Lys)6-Cys (SEQ ID NO: 92). While it is possible to prepare even longer polyacridine peptides of this design, we found the yields began to diminish. Each of the polyacridine peptides was coupled to PEG5000Da, resulting in PEGylated polyacridine peptide that produced a single symmetrical peak on RP-HPLC and a MALDI-TOF MS that verified the structure.
The primary structural features that influence the level of gene expression mediated by PEGylated polyacridine peptides was the presence of at least four Acr residues combined with cationic (Lys or Arg) spacing amino acid. PEGylated polyacridine peptides possessing four Acr residues spaced by either Glu or Leu demonstrated weak binding to DNA (
One of the more unique aspects of PEGylated polyacridine polyplexes is their open polyplex structures that resemble naked DNA (
PEGylated (Acr-Lys)6 (SEQ ID NO: 33) binds to DNA with higher affinity compared to all other peptides studied (
Pharmacokinetic and biodistribution studies were used to gain insight into the underlying mechanism of how delayed hydrodynamic stimulation caused PEGylated (Acr-Lys)6 polyplexes (SEQ ID NO: 33) to mediate gene expression in the liver. The most striking result was the apparent long pharmacokinetic half-life of PEGylated (Acr-Lys)4 (SEQ ID NO: 29) and PEGylated (Acr-Lys)6 polyplexes (SEQ ID NO: 33), compared to the rapid loss of 125I-DNA and PEGylated (Acr-Lys)2 polyplexes (SEQ ID NO: 32) (
These results cannot be directly compared with several prior studies that reported long circulating DNA or siRNA formulations by analyzing the pharmacokinetics of polyplexes by incorporating a fluorophore radiolabel into the carrier component (Heyes J et al. Lipid encapsulation enables the effective systemic delivery of polyplex plasmid DNA. Mol Ther 2007; 15: 713-720; Kunath K et al. The Structure of PEG-Modified Poly(Ethylene Imines) Influences Biodistribution and Pharmacokinetics of Their Complexes with NF-κB Decoy in Mice. Pharmaceutical Research 2002; 19: 810-817; Li S-D, Chen Y-C, Hackett M J, Huang L. Tumor-targeted Delivery of siRNA by Self-assembled Nanoparticles. Mol Ther 2007; 16: 163-169; Morille M et al. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials; 31: 321-329). These prior studies are more closely related in their direct analysis of pharmacokinetics using radiolabeled DNA45,46 or by quantifying DNA in blood and tissues by PCR (Zhou Q-H, Wu C, Manickam D, Oupicý D. Evaluation of Pharmacokinetics of Bioreducible Gene Delivery Vectors by Real-time PCR. Pharmaceutical Research 2009; 26: 1581-1589). These reports establish the ability to extend the half-life of DNA in the circulation, but stop short of establishing the metabolic status of recovered DNA. This is the first study to demonstrate stabilized plasmid DNA circulating in mice by gel electrophoresis and autoradiography. The metabolic stability of DNA is directly related to the mode and affinity of binding achieved by PEGylated (Acr-Lys)6 (SEQ ID NO: 33). A similar PEGylated polylysine peptide (PEG-Cys-Trp-Lys18 (SEQ ID NO: 34)) also binds with high affinity to DNA through ionic interaction and forms cationic-closed polyplexes (Kwok K Y, McKenzie D L, Evers D L, Rice K G. Formulation of highly soluble poly(ethylene glycol)-peptide DNA condensates. Journal of Pharmaceutical Sciences 1999; 88: 996-1003). However, despite being a longer peptide than PEGylated (Acr-Lys)6 (SEQ ID NO: 33), PEG-Cys-Trp-Lys18 polyplexes (SEQ ID NO: 34) rapidly dissociate following i.v. dosing leading to the complete metabolism of plasmid DNA in the circulation within 3 min (Collard W T et al. Biodistribution, metabolism, and in vivo gene expression of low molecular weight glycopeptide polyethylene glycol peptide DNA co-condensates. Journal of Pharmaceutical Sciences 2000; 89: 499-512). Thereby, it is the combination of polyintercalation and cationic binding that appears to be essential to achieve DNA stability during circulation, whereas PEGylated peptides that bind DNA by either mode individually are insufficient. This unique feature suggests that PEGylated (Acr-Lys)6 polyplexes (SEQ ID NO: 33) may find application in targeting DNA to tissues outside the liver.
Analysis of the tissue distribution of 125I-DNA polyplexes over time established the liver as the major site of distribution accounting for approximately 54-69% of the dose within the first 5 min, with only minor (<1%) distribution to other organs. PEGylated (Acr-Lys)4 (SEQ ID NO: 29) and PEGylated (Acr-Lys)6 polyplexes (SEQ ID NO: 33) produced a distinct liver distribution and metabolism profile, with maximal accumulation of 60% at 20 min followed by a decrease to 30% over two hrs (
In conclusion, this is the first report of high-level stimulated gene expression from a nonviral delivery system that mirrors the level of expression produced by the same dose administered by direct hydrodynamic dosing. The unique attributes of PEGylated polyacridine peptides establish their ability to form open or closed polyplex structures that stabilize DNA from metabolism in mice and allow a stimulation of a high volume rapid dose of saline to complete the gene transfer, even after a 1 hour delay following the primary dose. This is still only a starting point toward the development of a nonviral delivery system that produces high level expression in animals without stimulation. However, given the modularity of polyacridine peptides, it should be possible to build multi-component gene delivery systems that drive the DNA further toward the nucleus, to ultimately achieve this aim.
Gene therapy has been a goal of medicine for nearly 30 years. Current gene therapy research delivers DNA to tissues through the use of viruses, which have evolved their DNA delivery capabilities over millions of years. Viral gene delivery carries several risks, including immune response. These risks create an interest in nonviral gene delivery methods, however, nonviral techniques have long suffered from low efficiency in vivo compared to viral methods. It is believed that borrowing features from viruses may help to improve gene transfer efficiency. One such feature is phospholipase A2 activity seen in the capsid proteins of several viruses. When the PLA2 activity is removed, the virus becomes far less infective, implying PLA2 activity is important for delivering the viral genome into the host cell. We have developed a novel DNA nanoparticle incorporating bee venom PLA2 for gene delivery. PLA2 was attached to DNA using (Acr-Lys)6-Cys (SEQ ID NO: 92), a polyintercalating peptide previously developed by our lab. (Acr-Lys)6-Cys (SEQ ID NO: 92) was biotinylated on the c-terminal cysteine using a maleimide-biotin. PLA2 was randomly biotinylated on its lysines using a biotin NHS ester. The peptide and enzyme were then bound to avidin and DNA. We have confirmed that PLA2 is bound to DNA through an agarose gel assay and a PLA2 activity assay. This method is applicable to a wide variety of macromolecules, without covalently linking them to DNA, potentially creating a general system for anchoring many functionalities to DNA, without permanently damaging the DNA or hindering genetic processing. This ability could allow for efficient nonviral DNA delivery and gene therapy for the treatment of hereditary disorders, cancers, and other medical issues. A new compound has been generated that is a biotinylated polyacridine peptide that binds to DNA and also binds to Avidin. This compound is used to bind a biotinylated-enzyme (e.g., phospholipase A2, PLA2) onto DNA.
The inventors have established that PEGylated polyacridine peptides protect siRNA in the circulation. Atomic force microscopy (AFM) has provided direct evidence that PEGylated polyacridine peptides bind to siRNA to form polyplexes. Polyplex formation is essential to the formation of multi-component siRNA PEGylated PolyAcridine Peptides (PPAPs), since it is otherwise unlikely that more than two or three (Acr-Lys)6 (SEQ ID NO: 101) peptides will bind to a single siRNA of 22 bp. To achieve polyplex formation, (Acr-Lys)6 (SEQ ID NO: 101) would have to cross-link individual siRNA molecules. Not only would siRNA PPAPs form via cross-linking, but they would also need to be stable in the circulation. Several lines of evidence suggest this is the case. Binding of PEGylated (Acr-Lys)6 (SEQ ID NO: 33) caused a band shift of 125I-siRNA on PAGE. The formation of siRNA PPAPs with an average size of 50 nm diameter was determined by QELS and confirmed by AFM on anionic mica.
We have also now examined the pharmacokinetics of siRNA polyplexes in mice and have evidence that siRNA is protected in blood for up to 60 minutes. Pharmacokinetic analysis was used to determine if PEGylated (Acr-Lys)6 siRNA PPAPs (SEQ ID NO: 33) are stable in the circulation. We iodinated an all natural siRNA (22 bp) obtained from Dharmacon. The results established similar a-half-life for PEGylated (Acr-Lys)6 125I-siRNA PPAPs (SEQ ID NO: 33) compared to 125I-siRNA, but a much greater O-half-life, suggesting that PEGylated (Acr-Lys)6 siRNA PPAPs (SEQ ID NO: 33) are stable and circulate. Separation of blood time points by PAGE followed by detection by autoradiography indicate the siRNA is partially intact in blood for 60 min. We interpret the PAGE result as a composite of both RNA fragments excreted from liver and stable siRNA in blood. The results demonstrate the formation of siRNA PPAPs that have a long circulation in the blood.
We tested Man9-N-glycan polyacridine peptides as a DNA vaccine adjuvant for use in combination with an intramuscular electroporation apparatus. We generated data that demonstrated that we could bind up to 40 copies of Man9-(Acr-Lys)6 (SEQ ID NO: 42) to plasmid (as evidenced by DNA band shift assay), and preserve full gene expression by intramuscular electroporation. The Man9-(Acr-Lys)6 (SEQ ID NO: 42) that we used for this study has the following structure of In certain embodiments the compound is Formula IVb:
The Man9 N-glycan is derived from the pronase digestion of purified soy bean agglutinin (SBA). The Asn residue on Man9 was first modified by attaching Boc-Tyr the amine terminus followed by removal of Boc. The Tyr amine terminus was then derivatized with iodoacetic acid. The Iodoacetamide Man9 was then reacted Cys(Acr-Lys)6 (SEQ ID NO: 102) to form the product Man9-(Acr-Lys)6 (SEQ ID NO: 42).
The inventors obtained mouse data illustrating the electroporation apparatus expression of Man9-(Acr-Lys)6 (SEQ ID NO: 42) DNA (1 μg) at 0 and 0.012 nmoles of Man9-(Acr-Lys)6 (SEQ ID NO: 42) per μg of DNA (
Polyacridinylated peptides, which can be used in non-viral gene delivery, provide a reversible means of association with DNA via intercalation of base pairs, but limitations exist in regard to the size of a peptide synthesized via solid phase peptide synthesis (SPPS). Cysteine-flanked, acridinylated peptides were developed. Cysteines at the N- and C-termini of the peptide provide the additional feature of polymerization through disulfide bonding, and the affinity of the polymer for DNA will increase with greater incorporation of monomer. Disulfide bonding is also an attractive feature due to its ability to be reduced in the reductive intracellular environment.
CKacrKKacrC (SEQ ID NO: 103), CKacrRKacrC (SEQ ID NO: 104), CKacrLKacrC (SEQ ID NO: 105), and CKacrFKacrC (SEQ ID NO: 106) (where Kacr is a lysine modified with acridine at the ε-amine) (
To overcome complex insolubility, similar peptides conjugated via maleimide linkage to poly(ethylene glycol) (i.e., CKKacrCmal-mPEGKacrKC (SEQ ID NO: 43)) are made. Exemplary compounds include the following:
These peptides were made by solid phase peptide synthesis using an orthogonal protection scheme for Cys reported by Park et al. that allowed selective derivatization of the central Cys residue with PEG-maleimide. (Park, Y., Kwok, K. Y., Boukarim, C., and Rice, K. G., “Synthesis of Sulfhydryl Cross-Linking Poly(ethylene glycol)-Peptides and Glycopeptides as Carriers for Gene Delivery.” Bioconj. Chem. (2002) 13, 232-239)
All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification this invention has been described in relation to certain embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention.
The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
This application claims priority to U.S. Provisional Patent Application No. 61/320,726, filed Apr. 3, 2010, the entirety of which is incorporated herein by reference.
The invention described herein was made with government support under Grant Number DK066212, T32 GM067795, and RO1 GM087653 awarded by the National Institutes of Health. The United States Government has certain rights in this invention.
| Number | Date | Country | |
|---|---|---|---|
| 61320726 | Apr 2010 | US |
